

Financial news for VRTX dated on 2020-06-10: Vertex Earlier Announced European Commission Approval for KALYDECO for Children and Adolescents With Cystic Fibrosis Between the Ages of 6 Months and 18 Years With the R117H Mutation in the CFTR Gene

Financial news for VRTX dated on 2020-06-10: The Daily Biotech Pulse: Keytruda Setback For Merck, Denali Pulls The Plug On Neurological Asset

Financial news for VRTX dated on 2020-06-07: The Week Ahead In Biotech: Viela FDA Decision, Hematology Conference Take Center Stage

Financial news for VRTX dated on 2020-05-19: The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces \$1.34B Common Stock Offering

Financial news for VRTX dated on 2020-05-18: Stocks That Hit 52-Week Highs On Monday

Financial news for VRTX dated on 2020-05-15: Why Vertex's Stock Is Trading Higher Today

Financial news for VRTX dated on 2020-05-15: Vertex Pharmaceuticals shares are trading higher after Argus Research maintained a Buy rating and raised the price target from \$270 to \$320.

Financial news for VRTX dated on 2020-05-15: Argus Research Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to \$320

Financial news for VRTX dated on 2020-05-14: CIRSPR Therapeutics To Present New Data For CTX001 At European Hematology Association Congress Jun. 11-14

Financial news for VRTX dated on 2020-05-13: The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter

Financial news for VRTX dated on 2020-05-12: Stocks That Hit 52-Week Highs On Tuesday

Financial news for VRTX dated on 2020-05-12: Cramer Gives His Opinion On Cisco, Uber And More

Financial news for VRTX dated on 2020-05-12: The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands \$384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings

Financial news for VRTX dated on 2020-05-11: Vertex Pharmaceuticals shares are trading higher after the company and CRISPR were granted Regenerative Medicine Advanced Therapy Designation by the FDA for CTX001 for treatment of severe sickle cell disease.

Financial news for VRTX dated on 2020-05-11: Stocks That Hit 52-Week Highs On Monday

Financial news for VRTX dated on 2020-05-11: CRISPR Therapeutics, Vertex Pharma Report FDA Granted Regenerative Medicine Advanced Therapy Designation To CTX001 For Treatment Of Severe Sickle Cell Disease

Financial news for VRTX dated on 2020-05-08: 5 Biopharmas Where BofA Would Put Its Money To Work

Financial news for VRTX dated on 2020-05-01: Citigroup Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to \$305

Financial news for VRTX dated on 2020-05-01: The Daily Biotech Pulse: Gilead Slips Despite Forecast-Beating Q1, Moderna Partners With Lonza For Coronavirus Vaccine Production, Lyra Therapeutics IPO

Financial news for VRTX dated on 2020-05-01: Vertex Receives European CHMP Positive Opinion for KALYDECO for Children and Adolescents With Cystic Fibrosis Between the Ages 6 Months and 18 Years With the R117H Mutation in the CFTR Gene

Financial news for VRTX dated on 2020-04-30: CFRA Earlier Maintained Buy on Vertex Pharmaceuticals, Raised Price Target to \$297

Financial news for VRTX dated on 2020-04-30: Guggenheim Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to \$290

Financial news for VRTX dated on 2020-04-30: BMO Capital Maintains Outperform on Vertex Pharmaceuticals, Raises Price Target to \$283

Financial news for VRTX dated on 2020-04-30: Oppenheimer Maintains Outperform on Vertex Pharmaceuticals, Raises Price Target to \$305

Financial news for VRTX dated on 2020-04-30: Stifel Maintains Buy on Vertex

Pharmaceuticals, Raises Price Target to \$285

Financial news for VRTX dated on 2020-04-30: Morgan Stanley Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to \$277

Financial news for VRTX dated on 2020-04-30: JMP Securities Maintains Market Outperform on Vertex Pharmaceuticals, Raises Price Target to \$285

Financial news for VRTX dated on 2020-04-30: Vertex Pharmaceuticals shares are trading higher after the company reported better-than-expected Q1 EPS and sales results.

Financial news for VRTX dated on 2020-04-30: The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Hologic To Launch Coronavirus Test, Amarin's Strong Q1

Financial news for VRTX dated on 2020-04-30: HC Wainwright & Co. Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to \$295

Financial news for VRTX dated on 2020-04-30: SVB Leerink Maintains Market Perform on Vertex Pharmaceuticals, Raises Price Target to \$263

Financial news for VRTX dated on 2020-04-29: Vertex Pharmaceuticals Q1 EPS \$2.560 Beats \$1.840 Estimate, Sales \$1.520B Beat \$1.290B Estimate

Financial news for VRTX dated on 2020-04-29: The Daily Biotech Pulse: Inovio's MERS Vaccine Data, Fast Track Designation For Erytech, FDA Approves Higher Dose Of Merck's Keytruda

Financial news for VRTX dated on 2020-04-29: Earnings Scheduled For April 29, 2020

Financial news for VRTX dated on 2020-04-28: Why Vertex's Stock Is Trading Lower Today

Financial news for VRTX dated on 2020-04-28: Vertex Pharmaceuticals shares are trading lower after RBC analysts downgraded the company's stock from Outperform to Sector Perform.

Financial news for VRTX dated on 2020-04-28: Benzinga's Top Upgrades, Downgrades For April 28, 2020

Financial news for VRTX dated on 2020-04-28: RBC Capital Downgrades Vertex Pharmaceuticals to Sector Perform, Raises Price Target to \$260

Financial news for VRTX dated on 2020-04-27: Vertex Reports Multi-Year Collaboration Deal With Affinia Therapeutics For Discovery, Development Of Novel Adeno-Associated Virus Capsids For Genetic Therapies

Financial news for VRTX dated on 2020-04-26: The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight

Financial news for VRTX dated on 2020-04-24: The Daily Biotech Pulse: FDA Approves Sanofi's Meningococcal Vaccine, Pluristem Secures \$54M In Funding For COVID-19 Treatment, Oric Pharma Prices IPO

Financial news for VRTX dated on 2020-04-23: Shares of several healthcare companies are trading higher. Movement appears market-related as equities gain amid a rebound in oil prices.

Financial news for VRTX dated on 2020-04-22: The Daily Biotech Pulse: Immunic To Develop COVID Treatment, Gilead Strikes IO Partnership

Financial news for VRTX dated on 2020-04-21: Shares of several healthcare companies are trading lower with the overall market on continued downward momentum after oil prices fell to historic lows, partially stemming from weak demand caused by the coronavirus pandemic.

Financial news for VRTX dated on 2020-04-21: Stocks That Hit 52-Week Highs On Tuesday

Financial news for VRTX dated on 2020-04-21: The Daily Biotech Pulse: Applied DNA Begins Validating COVID-19 Test, Cara's Positive Readout, Novan Explores Strategic Alternatives

Financial news for VRTX dated on 2020-04-21: Vertex Announces Innovative Reimbursement Agreement in Switzerland for ORKAMBI and SYMDEKO for Eligible Cystic Fibrosis Patients

Financial news for VRTX dated on 2020-04-20: Stocks That Hit 52-Week Highs On Monday

Financial news for VRTX dated on 2020-04-17: Stocks That Hit 52-Week Highs On Friday

Financial news for VRTX dated on 2020-04-16: Shares of several healthcare companies are trading higher. Strength could potentially be related to the increased demand in medical products stemming from the coronavirus pandemic.

Financial news for VRTX dated on 2020-04-15: Morgan Stanley Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to \$258

Financial news for VRTX dated on 2020-04-14: Shares of several healthcare companies are trading higher as markets gain on positive coronavirus outlook. Other potential positive sector catalysts include demand for therapies and medical supplies amid the coronavirus pandemic.

Financial news for VRTX dated on 2020-04-09: Cramer Weighs In On Uber, Yelp And More

Financial news for VRTX dated on 2020-04-08: The Daily Biotech Pulse: Genmark Pre-Announces Q1 Outperformance, Sage to Eliminate 53% of Workforce, Keros IPO

Financial news for VRTX dated on 2020-04-07: The Daily Biotech Pulse: Sanofi, Regeneron Finalize Praluent Restructuring, Natus Pre-Announces Q1 Shortfall, Alcon To Delay Dividend Initiation

Financial news for VRTX dated on 2020-04-06: Shares of several healthcare companies are trading higher as markets gain amid optimism that coronavirus cases in several US hotspots may be peaking. A sooner peak could mean a sooner return to economic activity.

Financial news for VRTX dated on 2020-04-01: Shares of several healthcare companies are trading lower amid market weakness as growing coronavirus concerns in the US weigh on equities.

Financial news for VRTX dated on 2020-03-30: Shares of several healthcare companies are trading higher as the market rebounds on extended measures to help curb the coronavirus. NOTE: The sector could also be trading higher due to increased demand for medical products amid the coronavirus outbreak.

Financial news for VRTX dated on 2020-03-27: Shares of several healthcare companies are trading lower, selling off from this week's strength. While the US stimulus package boosted economic optimism, demand concerns still exist amid the coronavirus outbreak.

Financial news for VRTX dated on 2020-03-27: 10 Stocks To Buy With Low Debt And High Liquidity

Financial news for VRTX dated on 2020-03-25: Vertex Pharmaceuticals shares are trading lower, not currently seeing company-specific news. Movement appears market related as equities experience volatility amid US stimulus progress.

Financial news for VRTX dated on 2020-03-24: Shares of several healthcare companies are trading higher as equities gain amid hopes of a US stimulus agreement. Additionally, the coronavirus outbreak has increased demand for certain medical supplies.

Financial news for VRTX dated on 2020-03-23: Shares of several healthcare companies are trading higher the Fed announced actions to support the U.S. economy. The Fed will do open-ended treasury, mortgage-backed securities and will buy \$375 billion in treasury this week.

Financial news for VRTX dated on 2020-03-20: Shares of several healthcare companies are trading higher as the market rebounds from coronavirus-related selloffs.

Financial news for VRTX dated on 2020-03-16: Shares of several healthcare companies are trading lower as the coronavirus outbreak continues to cause economic disruption around the globe, leading to a steep selloff in equities across sectors.

Financial news for VRTX dated on 2020-03-12: Shares of several healthcare companies are trading lower as equities sell off amid continued global coronavirus concerns. The virus has caused global economic disruption and negatively impacted stocks across sectors.

Financial news for VRTX dated on 2020-03-11: 10 Biggest Price Target Changes For Wednesday

Financial news for VRTX dated on 2020-03-11: Shares of several healthcare companies are trading lower. Movement appears market related amid selloff in equities. The global coronavirus outbreak has caused volatility in global markets and impacted stocks across sectors.

Financial news for VRTX dated on 2020-03-11: Cantor Fitzgerald Reiterates Overweight

on Vertex Pharmaceuticals, Raises Price Target to \$275

Financial news for VRTX dated on 2020-03-09: Shares of several healthcare companies are trading lower. Movement appears market-related as markets continue to dip amid the global coronavirus outbreak and OPEC failing to reach production agreement.

Financial news for VRTX dated on 2020-03-09: Vertex Reports Coronavirus Outbreak Has Not Impacted Co.s Supply Chains Or 2020 Business Outlook

Financial news for VRTX dated on 2020-03-06: Shares of several healthcare companies are trading lower. Movement appears market related as markets continue to dip amid the global coronavirus outbreak.

Financial news for VRTX dated on 2020-03-05: Shares of several healthcare companies are trading lower. Weakness appears market related as equities across sectors continue to sell off amid coronavirus concerns. NOTE: The sector spiked yesterday following U.S. Democratic primary results.

Financial news for VRTX dated on 2020-03-04: Shares of several drugmakers and healthcare companies are trading higher following US Super Tuesday results in which Joe Biden won the highest number of delegates. Biden's more 'moderate' healthcare policies have been seen as more favorable for the sector.

Financial news for VRTX dated on 2020-03-02: Vertex Announces Cancellation Of March 3 Presentation At Cowen Health Care Conference

Financial news for VRTX dated on 2020-02-28: Shares of several healthcare companies are trading lower as the global coronavirus spread continues to cause equities across sectors to sell off amid worsened economic outlook.

Financial news for VRTX dated on 2020-02-27: Shares of several healthcare companies are trading lower as growing coronavirus fears hamper economic outlook.

Financial news for VRTX dated on 2020-02-25: Vertex Reports KALYDECO Now Available In New Zealand

Financial news for VRTX dated on 2020-02-24: Shares of several healthcare and biotech companies are trading lower amid continued spread of coronavirus including notable upticks in Iran and Italy. NOTE: The virus has raised fear of a global economic slowdown.

Financial news for VRTX dated on 2020-02-20: The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study

Financial news for VRTX dated on 2020-02-12: The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data

Financial news for VRTX dated on 2020-02-11: Stocks That Hit 52-Week Highs On Tuesday

Financial news for VRTX dated on 2020-02-11: The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology

Financial news for VRTX dated on 2020-02-07: The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns

Financial news for VRTX dated on 2020-02-06: Stocks That Hit 52-Week Highs On Thursday

Financial news for VRTX dated on 2020-02-06: The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs

Financial news for VRTX dated on 2020-02-05: Stocks That Hit 52-Week Highs On Wednesday

Financial news for VRTX dated on 2020-02-05: The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data

Financial news for VRTX dated on 2020-02-04: Shares of healthcare companies are trading higher amid a rebound in global equities following last week's selloff on coronavirus fears.

Financial news for VRTX dated on 2020-01-31: B of A Securities Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to \$295

Financial news for VRTX dated on 2020-01-31: Morgan Stanley Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to \$251

Financial news for VRTX dated on 2020-01-31: CFRA Maintains Buy on Vertex

Pharmaceuticals, Raises Price Target to \$286

Financial news for VRTX dated on 2020-01-31: RBC Capital Maintains Outperform on Vertex Pharmaceuticals, Raises Price Target to \$260

Financial news for VRTX dated on 2020-01-31: Stocks That Hit 52-Week Highs On Friday

Financial news for VRTX dated on 2020-01-31: Stifel Nicolaus Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to \$275

Financial news for VRTX dated on 2020-01-31: The Daily Biotech Pulse: Amgen Hurt By Generic Competition, Nanoviricides Confirms Working On Wuhan Virus, Arcutis IPO

Financial news for VRTX dated on 2020-01-31: Credit Suisse Maintains Outperform on Vertex Pharmaceuticals, Raises Price Target to \$258

Financial news for VRTX dated on 2020-01-31: 10 Biggest Price Target Changes For Friday

Financial news for VRTX dated on 2020-01-31: Vertex Pharmaceuticals shares are trading higher after the company reported better-than-expected Q4 EPS and sales results. The company issued FY20 sales guidance above analyst estimates.

Financial news for VRTX dated on 2020-01-31: Baird Downgrades Vertex Pharmaceuticals to Neutral, Raises Price Target to \$230

Financial news for VRTX dated on 2020-01-30: Vertex Sees FY20 Sales \$5.1B-\$5.3B vs \$4.87B Estimate

Financial news for VRTX dated on 2020-01-30: Vertex Pharmaceuticals Q4 Adj. EPS \$1.7 Beats \$1.2 Estimate, Sales \$1.257B Beat \$1.01B Estimate

Financial news for VRTX dated on 2020-01-30: The Daily Biotech Pulse: Sanofi Reports Positive Readout, Tonix Vaccine Candidate Aces Animal Study, Hologix's Weak Guidance

Financial news for VRTX dated on 2020-01-30: Earnings Scheduled For January 30, 2020

Financial news for VRTX dated on 2020-01-23: The Daily Biotech Pulse: Roche Reports Positive SMA Data Readout, Vir Biotech To Work On Virus Treatment

Financial news for VRTX dated on 2020-01-22: Stocks That Hit 52-Week Highs On Wednesday

Financial news for VRTX dated on 2020-01-22: The Daily Biotech Pulse: Johnson & Johnson Earnings, FDA Nod For Horizon Therapeutics, Slew Of Secondary Offerings

Financial news for VRTX dated on 2020-01-21: Stocks That Hit 52-Week Highs On Tuesday

Financial news for VRTX dated on 2020-01-20: 7 Blockbuster Drugs Expected To Be Launched In 2020

Financial news for VRTX dated on 2020-01-17: Stocks That Hit 52-Week Highs On Friday

Financial news for VRTX dated on 2020-01-17: The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares

Financial news for VRTX dated on 2020-01-16: Stocks That Hit 52-Week Highs On Thursday

Financial news for VRTX dated on 2020-01-15: Stocks That Hit 52-Week Highs On Wednesday

Financial news for VRTX dated on 2020-01-10: A Preview Of JPMorgan's Healthcare Conference: Focus On Value-Creating Themes, 2020 Expectations

Financial news for VRTX dated on 2020-01-10: The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx

Financial news for VRTX dated on 2020-01-09: Stocks That Hit 52-Week Highs On Thursday

Financial news for VRTX dated on 2020-01-09: The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, DBV Announces Positive Peanut Allergy Study Findings, Applied Genetic Soars On Trial Results

Financial news for VRTX dated on 2020-01-08: Oppenheimer Maintains Outperform on Vertex Pharmaceuticals, Raises Price Target to \$265

Financial news for VRTX dated on 2020-01-08: Vertex shares are trading higher after Citigroup raised the price target of the stock from \$225 to \$265.

Financial news for VRTX dated on 2020-01-08: The Daily Biotech Pulse: Verastem In-Licenses Chugai's Tumor Drug, Midatech Surges On Positive Study Results

Financial news for VRTX dated on 2020-01-06: Vertex Pharmaceuticals shares are trading higher after PiperJaffray maintained an Overweight rating on the stock and raised the price target from \$247 to \$284.

Financial news for VRTX dated on 2020-01-06: 10 Biggest Price Target Changes For Monday

Financial news for VRTX dated on 2020-01-06: PiperJaffray Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to \$284

Financial news for VRTX dated on 2020-01-02: Benzinga's Top Upgrades, Downgrades For January 2, 2020

Financial news for VRTX dated on 2019-12-29: Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus

Financial news for VRTX dated on 2019-12-24: 10 Biotech M&A Targets Under The Scanner For 2020

Financial news for VRTX dated on 2019-12-23: A Perspective On Biopharma's Record M&A Run In 2019

Financial news for VRTX dated on 2019-12-18: JP Morgan Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to \$247

Financial news for VRTX dated on 2019-12-17: 8 Biotech Stocks Morgan Stanley Recommends For 2020

Financial news for VRTX dated on 2019-12-10: The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy \$3M In ContraFect Shares

Financial news for VRTX dated on 2019-12-10: Vertex Announces European Commission Approval For KALYDECO In Infants With Cystic Fibrosis Ages 6 Months To Less Than 12 Months With Certain Mutations In The CFTR Gene

Financial news for VRTX dated on 2019-12-09: 9 Most Overbought Stocks In The S&P 500

Financial news for VRTX dated on 2019-12-06: Stocks That Hit 52-Week Highs On Friday

Financial news for VRTX dated on 2019-12-06: The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend

Financial news for VRTX dated on 2019-12-05: Stocks That Hit 52-Week Highs On Thursday

Financial news for VRTX dated on 2019-12-05: The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission

Financial news for VRTX dated on 2019-12-02: Shares of several healthcare stocks are trading lower as US equities dip following escalating US-China tensions over Hong Kong. US Stocks further fell on worse-than-expected manufacturing data.

Financial news for VRTX dated on 2019-11-27: The Daily Biotech Pulse: Tonix Says No Surprises In FDA Meeting Minutes, Aravive Offering, FDA Nod For Qiagen

Financial news for VRTX dated on 2019-11-26: Stocks That Hit 52-Week Highs On Tuesday

Financial news for VRTX dated on 2019-11-26: The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug

Financial news for VRTX dated on 2019-11-25: Stocks That Hit 52-Week Highs On Monday

Financial news for VRTX dated on 2019-11-21: The Daily Biotech Pulse: Patent Win For Collectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon

Financial news for VRTX dated on 2019-11-20: Bank of America Reiterates Buy on Vertex Pharmaceuticals, Raises Price Target to \$245

Financial news for VRTX dated on 2019-11-20: Stocks That Hit 52-Week Highs On Wednesday

Financial news for VRTX dated on 2019-11-20: The Daily Biotech Pulse: Endo's

Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data

Financial news for VRTX dated on 2019-11-19: Vertex Pharmaceuticals shares are trading higher after the company, along with CRISPR Therapeutics, announced positive, interim data from the investigational CRISPR/Cas9 gene-editing therapy CTX001 in ongoing Phase 1/2 clinical trials.

Financial news for VRTX dated on 2019-11-19: 51 Stocks Moving In Tuesday's Mid-Day Session

Financial news for VRTX dated on 2019-11-19: Crispr's Gene-Editing Therapy Found Effective In Treating Blood Disorders In Early-Stage Study

Financial news for VRTX dated on 2019-11-19: Cantor Fitzgerald Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to \$229

Financial news for VRTX dated on 2019-11-19: Stocks That Hit 52-Week Highs On Tuesday

Financial news for VRTX dated on 2019-11-19: The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout

Financial news for VRTX dated on 2019-11-19: CRISPR Therapeutics And Vertex Announce Safety And Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001 For Severe Hemoglobinopathies

Financial news for VRTX dated on 2019-11-18: Molecular Templates Announces Collaboration with Vertex Pharma, Molecular to Receive \$38M Upfront Payment Which Includes Equity Investment

Financial news for VRTX dated on 2019-11-15: Stocks That Hit 52-Week Highs On Friday

Financial news for VRTX dated on 2019-11-14: The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing

Financial news for VRTX dated on 2019-11-13: Stocks That Hit 52-Week Highs On Wednesday

Financial news for VRTX dated on 2019-11-13: The Daily Biotech Pulse: Merck Goes Shopping, Nuvecra Files For Bankruptcy Protection, Opiant Rips Higher

Financial news for VRTX dated on 2019-11-13: Vertex Confirms Wales Offer Accepted For Access To All Licensed Cystic Fibrosis Medicines

Financial news for VRTX dated on 2019-11-12: Vertex Issues Press Release Confirming Northern Ireland Offer Accepted By Cystic Fibrosis Medicines

Financial news for VRTX dated on 2019-11-12: Stocks That Hit 52-Week Highs On Tuesday

Financial news for VRTX dated on 2019-11-12: SunTrust Robinson Humphrey Initiates Coverage On Vertex Pharmaceuticals with Buy Rating, Announces \$235 Price Target

Financial news for VRTX dated on 2019-11-08: Vertex Pharmaceuticals shares are trading higher. Not currently seeing any company-specific news.

Financial news for VRTX dated on 2019-11-06: AstraZeneca Named The Most Innovative Global Pharma Company

Financial news for VRTX dated on 2019-11-01: Vertex Pharmaceuticals shares are trading higher on seemingly no company-specific news.

Financial news for VRTX dated on 2019-11-01: Stocks That Hit 52-Week Highs On Friday

Financial news for VRTX dated on 2019-11-01: Attention Biotech Investors: Mark Your Calendar For These November PDUFA Dates

Financial news for VRTX dated on 2019-11-01: The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek's Mixed Clinical Readout, CareDx Slips On Guidance

Financial news for VRTX dated on 2019-10-31: Piper Jaffray Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to \$247

Financial news for VRTX dated on 2019-10-31: Vertex Pharma Reports EMA Marketing Authorization Application Validation For VX-445, Tezacaftor, Ivacaftor Triple Combo Treatment In Cystic Fibrosis

Financial news for VRTX dated on 2019-10-31: Stifel Nicolaus Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to \$229

Financial news for VRTX dated on 2019-10-31: The Daily Biotech Pulse: Agile Receives Favorable Adcom Verdict, Merit Medical Tumbles On Earnings, 2 Biotechs To Debut

Financial news for VRTX dated on 2019-10-31: Morgan Stanley Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to \$250

Financial news for VRTX dated on 2019-10-30: Vertex Pharmaceuticals Reaffirms FY19 Product Revenues Guidance \$3.70B-\$3.75B

Financial news for VRTX dated on 2019-10-30: Vertex Pharmaceuticals Q3 EPS \$1.23 Beats \$1.13 Estimate, Sales \$950M Beat \$948.76M Estimate

Financial news for VRTX dated on 2019-10-30: Stocks That Hit 52-Week Highs On Wednesday

Financial news for VRTX dated on 2019-10-30: The Daily Biotech Pulse: Novartis Program Placed On Partial Clinical Hold, Adcom Snub For Amag, Amgen Earnings

Financial news for VRTX dated on 2019-10-30: Earnings Scheduled For October 30, 2019

Financial news for VRTX dated on 2019-10-29: 12 Stocks With The Highest Returns On Assets

Financial news for VRTX dated on 2019-10-28: BTIG: Crispr Could Be A Takeover Target For Vertex

Financial news for VRTX dated on 2019-10-28: CRISPR Shares Relatively Quiet As Traders Circulate Earlier Note From BTIG Suggesting 'Vertex's decision to exercise its options to in-license 3 added targets...could fuel speculation CRISPR will end up as Vertex takeover target.'

Financial news for VRTX dated on 2019-10-27: The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings

Financial news for VRTX dated on 2019-10-24: Vertex Pharma Reports Deal With NHS England For Access To All Licensed Cystic Fibrosis Medicines

Financial news for VRTX dated on 2019-10-24: Vertex Announces Agreement with NHS England for Access to All Licensed Cystic Fibrosis Medicines

Financial news for VRTX dated on 2019-10-22: Vertex Shares Are Rallying: What You Need To Know

Financial news for VRTX dated on 2019-10-22: 14 Stocks With The Highest Long-Term Projected Earnings Growth Rates

Financial news for VRTX dated on 2019-10-22: Vertex Pharmaceuticals shares are trading higher after Citigroup analysts maintained a Buy rating on the stock and raised the price target from \$205 to \$225.

Financial news for VRTX dated on 2019-10-22: Citigroup Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to \$225

Financial news for VRTX dated on 2019-10-21: Vertex Shares Resume Trade, Up 0.6%

Financial news for VRTX dated on 2019-10-21: Vertex Pharma Shares To Resume Trade At 4:20 p.m. EDT

Financial news for VRTX dated on 2019-10-21: Vertex 8-K Shows Raised FY19 CF Net Product Sales From \$3.6B-\$3.7B To \$3.7B-\$3.75B

Financial news for VRTX dated on 2019-10-21: Vertex Issues Press Release Confirming FDA Approval Of TRIKAFTA

Financial news for VRTX dated on 2019-10-21: Vertex Pharmaceuticals shares are trading higher after the FDA approved Trikafta for cystic fibrosis treatment.

Financial news for VRTX dated on 2019-10-21: Vertex Pharmaceuticals Shares Halted, News Pending

Financial news for VRTX dated on 2019-10-21: FDA Approves Vertex's Trikafta For Cystic Fibrosis Treatment

Financial news for VRTX dated on 2019-10-21: Vertex Pharma Reports Spanish Gov't. Has Approved Terms For National Reimbursement Of ORKAMBI, SYMKEVI In Combo With KALYDECO For Cystic Fibrosis Patients In Spain

Financial news for VRTX dated on 2019-10-20: Vertex Announces Reimbursement of Cystic

Fibrosis Medicines SYMDEKO for Eligible Patients Ages 12 and Older, and ORKAMBI in Children Ages 2 to 5, With Certain CFTR Mutations in Australia

Financial news for VRTX dated on 2019-10-18: Vertex Pharma Reports Positive CHMP Opinion For KAYLDECO to Treat Eligible Infants With Cystic Fibrosis As Early As 6 Months Of Age

Financial news for VRTX dated on 2019-10-17: Bank of America Reinstates Buy on Vertex Pharmaceuticals, Announces \$220 Price Target

Financial news for VRTX dated on 2019-09-30: Vertex and Ribometrix Announces Strategic Collaboration to Develop RNA-Targeted Small Molecule Therapeutics, Vertex to Make a \$20M Upfront Payment

Financial news for VRTX dated on 2019-09-26: Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator Elizabeth Warren in the lead.

Financial news for VRTX dated on 2019-09-24: Shares of many pharma/therapeutics stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.

Financial news for VRTX dated on 2019-09-11: 12 Stocks With The Most Earnings Upside Potential

Financial news for VRTX dated on 2019-09-06: Morgan Stanley Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to \$240

Financial news for VRTX dated on 2019-09-03: Vertex To Acquire Diabetes Treatment Company Semma Therapeutics For \$950M

Financial news for VRTX dated on 2019-09-03: Goldman Sachs Reiterates Buy on Vertex Pharmaceuticals, Raises Price Target to \$254; Adds To Conviction List

Financial news for VRTX dated on 2019-09-03: Vertex To Acquire Semma Therapeutics For \$950M In Cash; Co. Highlights 'Goal of Developing Curative Cell-Based Treatments for Type 1 Diabetes'

Financial news for VRTX dated on 2019-08-31: Barron's Picks And Pans: Activision Blizzard, Best Buy, Coca-Cola, Microsoft And More

Financial news for VRTX dated on 2019-08-28: 'Vertex sinks on reports of patient deaths tied to cystic fibrosis drug' -STAT

Financial news for VRTX dated on 2019-08-20: Vertex Pharmaceuticals Announces FDA Acceptance Of NDA For VX-445

Financial news for VRTX dated on 2019-08-19: Shares of several healthcare companies are trading higher as optimism increased for a resolution to the US-China trade war.

Financial news for VRTX dated on 2019-08-16: Shares of healthcare companies are trading higher as US markets rebound from recent weakness following a yield curve inversion, which caused recession fears. Trump also recently announced the US would delay China tariffs, renewing hopes of a trade deal.

Financial news for VRTX dated on 2019-08-01: Vertex Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 EPS and sales results.

Financial news for VRTX dated on 2019-08-01: Credit Suisse Maintains Outperform on Vertex Pharmaceuticals, Raises Price Target to \$213

Financial news for VRTX dated on 2019-08-01: Piper Jaffray Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to \$230

Financial news for VRTX dated on 2019-08-01: Stifel Nicolaus Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to \$211

Financial news for VRTX dated on 2019-08-01: Needham Downgrades Vertex Pharmaceuticals to Hold

Financial news for VRTX dated on 2019-07-31: The Daily Biotech Pulse: Roche-Spark Deal Faces Further Delay, Bayer's Prostate Cancer Drug Passes FDA Muster

Financial news for VRTX dated on 2019-07-31: Earnings Scheduled For July 31, 2019

Financial news for VRTX dated on 2019-07-27: The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate

Financial news for VRTX dated on 2019-07-25: Vertex Pharma Names Jeffrey Leiden Chair, Reshma Kewalramani CEO

Financial news for VRTX dated on 2019-07-22: Vertex Submits New Drug Application to the FDA for a Triple Combination Regimen of VX-445, Tezacaftor and Ivacaftor in Cystic Fibrosis

Financial news for VRTX dated on 2019-07-11: Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.

Financial news for VRTX dated on 2019-06-29: The Week Ahead In Biotech: Pending Clinical Readouts In Focus

Financial news for VRTX dated on 2019-06-21: Vertex Pharmaceuticals Confirms FDA Approval For SYMDEKO

Financial news for VRTX dated on 2019-06-21: FDA Grants Vertex Pharmaceuticals Expanded Indication For SYMDEKO Tablets For PEdiatric PATients With Cystic Fibrosis

Financial news for VRTX dated on 2019-06-07: Vertex Pharmaceuticals shares are trading higher after the company announced it acquired Exonics Therapeutics, expanding into gene therapy; The company also entered a licensing agreement with CRISPR to further help jump-start its gene-therapy business.

Financial news for VRTX dated on 2019-06-07: Vertex Signs Gene Editing Deals With Crispr, Exonics Worth Up To \$2 Billion

Financial news for VRTX dated on 2019-06-07: The Daily Biotech Pulse: Vertex Bets Big On Gene-Editing Therapies, Sanofi Poaches Novartis For CEO Role, Relief In Europe for Endologix

Financial news for VRTX dated on 2019-06-06: Vertex And CRISPR Therapeutics Enter Licensing Agreement To Discover And Develop Gene Therapies For DMD And DML; Vertex To Acquire Exonics For \$245M Plus Potential Milestones, CRISPR To Receive Upfront Payment Of \$175M

Financial news for VRTX dated on 2019-05-30: Vertex Pharma Reports Selected Triple Combo Of Next-Gen Corrector VX-445, Tezacaftor, Ivacaftor To Submit For Potential Global Regulatory Approvals For Peoples Ages 12+ With Cystic Fibrosis

Financial news for VRTX dated on 2019-05-23: Goldman Sachs Assumes Vertex Pharmaceuticals Incorporated - Common Stock at Buy, Announces Price Target \$220

Financial news for VRTX dated on 2019-05-21: Benzinga's Top Upgrades, Downgrades For May 21, 2019

Financial news for VRTX dated on 2019-05-21: Credit Suisse Initiates Coverage On Vertex Pharmaceuticals Incorporated - Common Stock with Outperform Rating, Announces \$209 Price Target

Financial news for VRTX dated on 2019-05-15: UPDATE: Vertex Says Kymera To Receive \$70M Upfront Payment, Including Equity Investment

Financial news for VRTX dated on 2019-05-15: Vertex Pharma, Kymera Therapeutics Report Establishment Of Strategic Collaboration To Discover, Develop Targeted Protein Degradation Medicines For Serious Diseases

Financial news for VRTX dated on 2019-05-14: Shares of several healthcare companies are trading higher as the US market rebounds from recent weakness, driven by renewed cautious optimism surrounding US-China trade talks.

Financial news for VRTX dated on 2019-05-01: Vertex Pharmaceuticals shares are trading higher after the company reported better-than-expected Q1 EPS and sales results.

Financial news for VRTX dated on 2019-04-30: Vertex Pharmaceuticals Q1 EPS \$1.14 Beats \$0.98 Estimate, Sales \$857M Beat \$850.93M Estimate

Financial news for VRTX dated on 2019-04-30: Shares of several healthcare companies are trading lower on continued uncertainty over healthcare policy as well as concerns over the medicare-for-all proposals among 2020 candidates.

Financial news for VRTX dated on 2019-04-30: Vertex Pharma Reports FDA Approval Of DALYDECO as First and Only CFTR Modulator to Treat Eligible Infants with CF as Early as Six Months of Age

Financial news for VRTX dated on 2019-04-30: The Daily Biotech Pulse: Earnings

Deluge, G1 Therapeutics Positive FDA Meeting, Mustang Bio Offering

Financial news for VRTX dated on 2019-04-30: Earnings Scheduled For April 30, 2019

Financial news for VRTX dated on 2019-04-27: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs

Financial news for VRTX dated on 2019-04-23: Shares of several healthcare stocks are trading higher in a potential rebound from last week's selloff. In an upgrade of HCA Healthcare, Raymond James analysts noted the selloff was 'based on legislation that has almost no chance of passing'

Financial news for VRTX dated on 2019-04-17: Shares of several healthcare companies are trading lower after Trump renewed his efforts to repeal and replace the Affordable Care Act; the Department of Justice moved to accelerate the appeal process in hopes to invalidate the ACA as unconstitutional.

Financial news for VRTX dated on 2019-04-16: CRISPR Therapeutics And Vertex Announce FDA Fast Track Designation For CTX001 For The Treatment Of Beta Thalassemia

Financial news for VRTX dated on 2019-04-12: Evercore ISI Group Initiates Coverage On Vertex Pharmaceuticals with In-Line Rating

Financial news for VRTX dated on 2019-04-10: Get In On Genomics With This New ETF

Financial news for VRTX dated on 2019-04-02: Vertex Pharma Names Charlie Wagner CFO

Financial news for VRTX dated on 2019-03-26: Benzinga's Top Upgrades, Downgrades For March 26, 2019

Financial news for VRTX dated on 2019-03-26: William Blair Upgrades Vertex Pharmaceuticals to Outperform

Financial news for VRTX dated on 2019-03-19: Benzinga's Top Upgrades, Downgrades For March 19, 2019

Financial news for VRTX dated on 2019-03-19: SVB Leerink Downgrades Vertex Pharmaceuticals to Market Perform

Financial news for VRTX dated on 2019-03-12: Vertex Pharmaceuticals Earlier Announced TGA Approval For SYMDEKO In Cystic Fibrosis

Financial news for VRTX dated on 2019-03-07: 7 Biggest Price Target Changes For Thursday

Financial news for VRTX dated on 2019-03-07: Oppenheimer Maintains Outperform on Vertex Pharmaceuticals, Raises Price Target to \$230

Financial news for VRTX dated on 2019-03-06: Vertex Reports Treatment With Triple Combo VX-445, Tezacaftor, Ivacaftor Resulted In Statistically Significant Improvements In Lung Function In 2 Phase 3 Studies For Cystic Fibrosis

Financial news for VRTX dated on 2019-03-05: Markets React Amid Report FDA Commish Scott Gottlieb Will Resign

Financial news for VRTX dated on 2019-02-25: CRISPR Therapeutics And Vertex Pharmaceuticals Incorporated Announce That The First Patient Has Been Enrolled In A Phase 1/2 Clinical Study Of Ctx001 In Severe Scd In The U.S. And Is Expected To Be Infused With Ctx001 In Mid-2019

Financial news for VRTX dated on 2019-02-25: CRISPR Therapeutics And Vertex Pharmaceuticals Incorporated Announce That The First Patient Has Been Treated With Ctx001 In A Phase 1/2 Clinical Study Of Patients With Transfusion-Dependent Beta Thalassemia

Financial news for VRTX dated on 2019-02-14: Vertex Reports Results From Phase 3 Study Of Tezacaftor In Combo With Ivacaftor In Children 6-11 With Cystic Fibrosis In Europe, Australia: Study Met Primary Endpoint

Financial news for VRTX dated on 2019-02-13: Vertex Pharma Filing Shows Registration For Mixed Securities Offering, No Size Disclosed

Financial news for VRTX dated on 2019-02-13: Hearing Alliance Bernstein Reduces Stakes In Apple, Facebook, Amazon, Citigroup, Crown Castle; Raises Stakes In Vertex Pharmaceuticals, Procter & Gamble, Regency Centers, Microsoft, Pfizer

Financial news for VRTX dated on 2019-02-06: The Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering

Financial news for VRTX dated on 2019-02-05: Vertex Pharmaceuticals Q4 EPS \$1.30 Beats \$1.06 Estimate, Sales \$868M Beat \$819.6M Estimate

Financial news for VRTX dated on 2019-02-05: Earnings Scheduled For February 5, 2019

Financial news for VRTX dated on 2019-01-28: Health Canada Grants Vertex Pharmaceuticals Market Authorization For KALYDECO In Children Ages 12 To <24 Months With Certain Mutations In The CFTR Gene

Financial news for VRTX dated on 2019-01-23: Vertex Pharma Reports Its Interim CFO, Ian Smith, To Leave Co., Cites 'personal behavior that violated Vertex's Code of Conduct and values and is unrelated to the Company's financial and business performance'

Financial news for VRTX dated on 2019-01-22: Vertex Pharmaceuticals On Monday Announced European Commission Approval Of ORKAMBI For Treatment Of Children With Cystic Fibrosis Aged 2 to 5 Years Old

Financial news for VRTX dated on 2019-01-16: Vertex Pharmaceuticals Option Alert: Fri \$185 Calls at the Ask: 500 @ \$2.0 vs 8524 OI; Earnings 1/30 After Close [est] Ref=\$185.932

Financial news for VRTX dated on 2019-01-04: Citigroup Maintains Buy on Vertex Pharmaceuticals, Lowers Price Target to \$205

Financial news for VRTX dated on 2019-01-04: CRISPR Therapeutics, Vertex Report FDA Fast Track Designation For CTX001 For Treatment Of Sickle Cell Disease

Financial news for VRTX dated on 2019-01-02: Benzinga's Top Upgrades, Downgrades For January 2, 2019

Financial news for VRTX dated on 2019-01-02: Raymond James Downgrades Vertex Pharmaceuticals to Market Perform

Financial news for VRTX dated on 2018-12-26: Crispr Therapeutics 10%+ Owner Vertex Pharmaceuticals Buys 90,742 @ Avg Price: \$24.08

Financial news for VRTX dated on 2018-12-26: 6 Valuable Pipeline Drugs With Upcoming Catalysts

Financial news for VRTX dated on 2018-12-26: HC Wainwright Bullish On Corbus Therapeutics' Cystic Fibrosis Opportunity

Financial news for VRTX dated on 2018-12-19: Vertex Pharma Reports Will Submit ORKAMBI, SYMKEVI To Be Used In Combo With Ivacaftor To Scottish Medicines Consortium For Appraisal

Financial news for VRTX dated on 2018-12-19: Morgan Stanley Maintains Overweight on Vertex Pharmaceuticals, Lowers Price Target to \$210

Financial news for VRTX dated on 2018-12-18: Biotechs Were Innovators In 2018: Here Are The Top New Molecules That Were Approved

Financial news for VRTX dated on 2018-12-18: Vertex Reports Positive Phase 2 Third Proof-Of-Concept Study With NaV1.8 Inhibitor VX-150 Met Its Primary Endpoint

Financial news for VRTX dated on 2018-12-18: Guggenheim Reinstates Neutral on Vertex Pharmaceuticals

Financial news for VRTX dated on 2018-12-17: Vertex Pharmaceuticals CFO Tom Graney Leaving Co. For Generation Bio

Financial news for VRTX dated on 2018-12-13: Vertex Pharma Reports Health Canada Granted Market Authorization For ORKAMBI For Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease

Financial news for VRTX dated on 2018-12-10: 5 Biotech Companies To Keep On Your M&A Watchlist For 2019

Financial news for VRTX dated on 2018-11-29: Vertex Announces EC Approval for KALYDECO to Treat Patients with Cystic Fibrosis Aged 12 to <24 months with Certain Mutations in the CFTR Gene

Financial news for VRTX dated on 2018-11-27: Vertex Pharmaceuticals shares are trading up 5.0% after the company reported two Phase 3 studies met primary endpoints.

Financial news for VRTX dated on 2018-11-27: Vertex Pharma Reports 2 Phase 3 Studies Of Triple Combo Of VX-659, Tezacaftor, Ivacaftor Met Primary Endpoint

Financial news for VRTX dated on 2018-11-16: Vertex Receives European CHMP Positive Opinion For ORKAMBI For Treatment Of Children With Cystic Fibrosis Aged 2 To 5 Years Old With Most Common Form Of The Disease

Financial news for VRTX dated on 2018-11-01: Vertex Announces EC for Third Cystic Fibrosis Medicine SYMKEVI to be Used in Combination with Ivacaftor for People with CF Aged 12 and Older with Certain Mutations in the CFTR Gene

Financial news for VRTX dated on 2018-10-26: Benzinga's Top Upgrades, Downgrades For October 26, 2018

Financial news for VRTX dated on 2018-10-26: H.C. Wainwright Upgrades Vertex Pharmaceuticals to Buy, Raises Price Target to \$220

Financial news for VRTX dated on 2018-10-25: Raymond James Maintains Outperform on Vertex Pharmaceuticals, Lowers Price Target to \$201

Financial news for VRTX dated on 2018-10-25: BMO Capital Maintains Outperform on Vertex Pharmaceuticals, Lowers Price Target to \$192

Financial news for VRTX dated on 2018-10-25: The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price

Financial news for VRTX dated on 2018-10-24: Vertex Sees FY18 CF Product Sales \$2.9B-\$3B

Financial news for VRTX dated on 2018-10-24: Vertex Pharmaceuticals Incorporated Q3 Adj. EPS \$1.09 Beats \$1.01 Estimate, Sales \$784.535M Miss \$787.32M Estimate

Financial news for VRTX dated on 2018-10-24: Vertex Pharmaceuticals Q3 Earnings Outlook

Financial news for VRTX dated on 2018-10-24: The Daily Biotech Pulse: Illumina's Strong Q3, Celgene's Positive Cancer Drug Trial, Proteostasis Offering

Financial news for VRTX dated on 2018-10-24: Earnings Scheduled For October 24, 2018

Financial news for VRTX dated on 2018-10-21: The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results, Large-Cap Pharma Earnings And IPOs

Financial news for VRTX dated on 2018-10-19: Vertex Receives European CHMP Positive Opinion For KALYDECO To Treat Patients With Cystic Fibrosis Aged 12 to <24 Months With Certain Mutations In The CFTR Gene

Financial news for VRTX dated on 2018-10-18: Vertex Data To Be Presented At North American Cystic Fibrosis Conference (NACFC) October 18-20

Financial news for VRTX dated on 2018-10-18: Hearing Morgan Stanley Out Defending Vertex After Potential Competitor, Proteostasis, Released Phl Data; Firm Says Would 'Caution' Over-Interpretation Of Proteostasis Data As It Only Includes ~5 Patient Arm, Sweat Chloride Reduction Was 'Modest

Financial news for VRTX dated on 2018-10-16: Surverying The Q3 Earnings Heat Map

Financial news for VRTX dated on 2018-10-11: The Daily Biotech Pulse: Clinical Hold Lifted Off Crispr's Gene-Edited Therapy, Endra To Offer Shares

Financial news for VRTX dated on 2018-10-10: CRISPR Therapeutics and Vertex Announce FDA Lifted Clinical Hold on CTX001

Financial news for VRTX dated on 2018-10-05: Vertex Pharma Shares Appear Unaffected Over Last Few Mins As Traders Circulate Canadian Officials Recommending Co.'s Drug Should Not Be Eligible For Reimbursement

Financial news for VRTX dated on 2018-10-02: Stocks Which Set New 52-Week High Yesterday, October 1st

Financial news for VRTX dated on 2018-10-01: Cantor Fitzgerald Initiates Coverage On Vertex Pharmaceuticals with Overweight Rating, Announces \$217 Price Target

Financial news for VRTX dated on 2018-10-01: Vertex Announces Access Contract In Denmark For Current And Future Cystic Fibrosis Medicines

Financial news for VRTX dated on 2018-09-28: The Daily Biotech Pulse: FDA Nods For Adamis, Eli Lilly, Pfizer; Spero, Obseva Report Positive Trial Results

Financial news for VRTX dated on 2018-09-27: Stocks That Made New 52-Week Highs So Far Today Include: TJX Companies, HCA Healthcare , Vertex Pharma, F5 Networks, Amgen, Tractor Supply, Visa, Illumina, Cooper Companies, CF Industries, Activision Blizzard,

Salesforce, and Aon

Financial news for VRTX dated on 2018-09-27: Stocks Which Set New 52-Week High Yesterday, September 26th

Financial news for VRTX dated on 2018-09-27: The Daily Biotech Pulse: Hologic Goes Shopping, Johnson & Johnson Snaps Ties With Geron

Financial news for VRTX dated on 2018-09-26: Stocks That Made New 52-Week Highs So Far Today Include: Becton Dickinson, PerkinElmer, TJX Companies, Medtronic, Danaher, Mastercard, Visa, Illumina, Motorola Solutions, Salesforce, Ross Stores, Edward Lifesciences, and Boston Scientific

Financial news for VRTX dated on 2018-09-06: '\$VRTX Phase 3 data readouts for triple regimen (cystic fibrosis) in late 2018. Enrollment just completed. Pretty much as expected (hoped for.)'-STAT's Adam Feuerstein Tweets

Financial news for VRTX dated on 2018-09-06: Vertex Reports Completion Of Enrollment Of 2 Phase 3 Studies Of VX-659 In Triple Combo With Tezacaftor, Ivacaftor For Treatment Of Cystic Fibrosis

Financial news for VRTX dated on 2018-09-04: Vertex Pharmaceuticals On Monday Announced Reimbursement Agreement In Australia For ORKAMBI In Cystic Fibrosis

Financial news for VRTX dated on 2018-08-31: 'First company-sponsored trial of CRISPR in patients launches' -STAT News

Financial news for VRTX dated on 2018-08-30: Stocks Which Set New 52-Week High Yesterday, August 29th

Financial news for VRTX dated on 2018-08-30: The Daily Biotech Pulse: Verastem Gets New CFO, Mesoblast Earnings, Vertex's Precision Medicine Collaboration

Financial news for VRTX dated on 2018-08-29: Stocks That Made New 52-Week Highs So Far Today Include: Salesforce, Textron, TJX, Kansas City Southern, Dover, HCA, United Continental, Ingersoll-Rand, Xilinx, Thermo Fisher, Progressive, Microsoft, Apple, Paypal, Cisco, UnitedHealth, Visa & Mastercard

Financial news for VRTX dated on 2018-08-20: Vertex Receives Positive PBAC Recommendation for Reimbursement of ORKAMBI to Treat Australians Ages Six and Over with Cystic Fibrosis and Two Copies of the F508del Mutation

Financial news for VRTX dated on 2018-08-15: Vertex Pharmaceuticals Announces FDA Approval Of KALYDECO As First And Only Medicine To Treat Underlying Cause Of CF In Children Ages 12 to <24 Months With Certain Mutations In CFTR Gene

Financial news for VRTX dated on 2018-08-15: Vertex Pharma Has fda PDUFA Date Today for ORKAMBI in Kids 12 to Under 2 Years of Age; BZ NOTE: Co. Received Approval For ORKAMBI in 2-5 Year Olds August 7th

Financial news for VRTX dated on 2018-08-15: The Daily Biotech Pulse: Vertex Awaits FDA Verdict, Strongbridge Falls On Offering, ReShape's Woes Continue

Financial news for VRTX dated on 2018-08-13: The Week Ahead: Nvidia, Retailer Earnings In Focus

Financial news for VRTX dated on 2018-08-12: The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs

Financial news for VRTX dated on 2018-08-07: Vertex Pharma Reports FDA Approved ORKAMBI For Treatment Of Underlying Cause Of Cystic Fibrosis For Children Ages 2-5 Years With Most Common Form Of Disease

Financial news for VRTX dated on 2018-08-07: Stifel Transfers Coverage Of Vertex Pharmaceuticals With A Buy And \$200 Price Target

Financial news for VRTX dated on 2018-08-07: The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel

Financial news for VRTX dated on 2018-08-07: REMINDER: Vertex Pharma Has FDA PDUFA Date Today for Ivacaftor for Cystic Fibrosis

Financial news for VRTX dated on 2018-08-06: The Week Ahead: Earnings From Disney, Roku And Snap, Rite Aid Votes On Albertsons Deal

Financial news for VRTX dated on 2018-08-05: The Week Ahead In Biotech: Conferences, PDUFA Dates And IPOs

Financial news for VRTX dated on 2018-07-30: Citigroup Maintains Buy on Vertex

Pharmaceuticals, Raises Price Target to \$206

Financial news for VRTX dated on 2018-07-28: The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs

Financial news for VRTX dated on 2018-07-27: European Union Medicines Agency Has Recommended Approval For Vertex Pharma's Tezacaftor/Ivacaft Cystic Fibrosis Combo Treatment

Financial news for VRTX dated on 2018-07-26: UBS Maintains Neutral on Vertex Pharmaceuticals, Raises Price Target to \$188

Financial news for VRTX dated on 2018-07-26: Benzinga's Daily Biotech Pulse: Biogen, AC Immune Slip Despite Positive Trials, Sarepta Slapped With Clinical Hold

Financial news for VRTX dated on 2018-07-26: Morgan Stanley Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to \$211

Financial news for VRTX dated on 2018-07-25: Vertex Pharmaceuticals Raises FY18 Cystic Fibrosis Product Sales Outlook From \$2.65B-\$2.80B To \$2.9B-\$3B

Financial news for VRTX dated on 2018-07-25: Vertex Pharmaceuticals Q2 Adj. EPS \$0.94 Beats \$0.75 Estimate, Sales \$751.22M Beat \$682.24M Estimate

Financial news for VRTX dated on 2018-07-25: Benzinga's Daily Biotech Pulse: Merck's Keytruda Found Effective, Nabriva To Acquire Zavante, FDA Denies Agile

Financial news for VRTX dated on 2018-07-25: Earnings Preview For Vertex Pharmaceuticals

Financial news for VRTX dated on 2018-07-22: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs

Financial news for VRTX dated on 2018-07-18: Benzinga's Daily Biotech Pulse: Novartis Earnings, J&J's HIV Combo Clears FDA Hurdle, Cara To Offer Shares

Financial news for VRTX dated on 2018-07-17: Stocks That Made New 52-Week Highs Today Include: Citrix, TripAdvisor, Microsoft, Alphabet (Both Classes), Medtronic, Accenture, Facebook, NetApp, S&P Global, Amazon, VeriSign, Motorola Solutions, Marsh & McLennan, IDEXX Labs, Eli Lilly, Sysco, and VF

Financial news for VRTX dated on 2018-07-13: Benzinga's Daily Biotech Pulse: Amgen Resubmits Osteoporosis Drug BLA, Auris Medical Prices Offering

Financial news for VRTX dated on 2018-07-02: 44 Biggest Movers From Friday

Financial news for VRTX dated on 2018-06-29: 35 Stocks Moving In Friday's Mid-Day Session

Financial news for VRTX dated on 2018-06-29: Benzinga's Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos

Financial news for VRTX dated on 2018-06-29: 24 Stocks Moving In Friday's Pre-Market Session

Financial news for VRTX dated on 2018-06-28: Health Canada Approves Vertex's PrSYMDEKO

Financial news for VRTX dated on 2018-06-18: Vertex Reports Long-Term Access Agreement in Sweden for Cystic Fibrosis Medicine ORKAMBI

Financial news for VRTX dated on 2018-06-07: Vertex Data Presented At European Cystic Fibrosis Society (ECFS) Conference Demonstrate Early And Long-Term Disease-Modifying Potential Of Treating The Underlying Cause Of Cystic Fibrosis

Financial news for VRTX dated on 2018-06-07: Vertex Data Presented at European Cystic Fibrosis Society (ECFS) Conference Demonstrate Early and Long-Term Disease-Modifying Potential of Treating the Underlying Cause of CF

Financial news for VRTX dated on 2018-05-31: 3 Possible Outcomes From The Clinical Hold On Crispr Therapeutics's Sickel Cell Candidate

Financial news for VRTX dated on 2018-05-31: Benzinga's Daily Biotech Pulse: Clinical Hold For Crispr, Gilead Study Meets Endpoint, Akers Gets Grace Time

Financial news for VRTX dated on 2018-05-30: CRISPR and Vertex Pharma Announce FDA Has Placed A Clinical Hold on IND For CTX001 Pending Resolution Of 'Certain Questions' As Part of Its Review

Financial news for VRTX dated on 2018-04-27: Morgan Stanley Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to \$207.00

Financial news for VRTX dated on 2018-04-27: Benzinga's Daily Biotech Pulse: Intracellular Moves On Poster Presentation, Earnings Beats From Vertex, Exact Sciences

Financial news for VRTX dated on 2018-04-26: Vertex Pharma Sees FY18 Sales \$2.65B-\$2.8B vs \$2.78B Est.

Financial news for VRTX dated on 2018-04-26: Vertex Pharma Q1 Adj. EPS \$0.76 Beats \$0.62 Est., Sales \$638M Beats \$617.59M Est.

Financial news for VRTX dated on 2018-04-26: Vertex Initiates Phase 3 Studies Of VX-445, Tezacaftor And Ivacaftor As A Triple Combination Regimen For Cystic Fibrosis

Financial news for VRTX dated on 2018-04-26: Benzinga's Daily Biotech Pulse: Catabasis Soars On Trial Results, Eloxx Listing, Biomarin Earnings

Financial news for VRTX dated on 2018-04-20: The Week Ahead In Biotech: PDUFA Dates, IPOs And More

Financial news for VRTX dated on 2018-04-04: Vertex Pharma, Q-State Biosciences Report Strategic Collab To Discover Drugs Using Q-State's Novel Optopatch Platform

Financial news for VRTX dated on 2018-03-20: Proteostasis Tumbles 25% After Short Seller Calls Leading Drug Candidate 'A Dud'

Financial news for VRTX dated on 2018-03-16: Baird: Prospects For Proteostasis Therapeutics' PTI-428 Are Not Priced Into The Stock

Financial news for VRTX dated on 2018-03-01: Vertex Pharma Reports Initiation Of Phase 3 Study Of VX-659, Tezacaftor, Ivacaftor As Triple Combo Regimen For People With CF Who Have 2 Copies Of F508del Mutation

Financial news for VRTX dated on 2018-02-26: 46 Biggest Movers From Yesterday

Financial news for VRTX dated on 2018-02-21: Adam Feuerstein Tweet: I spoke w/ \$VRTX. They will report ph3 top-line results AFTER 12 week safety is collected. (Not at 4 week efficacy.) They will also file once 12-week safety is collected. No timeline yet on when we could see top-line r

Financial news for VRTX dated on 2018-02-21: Vertex Initiates Phase 3 VX-659 Study

Financial news for VRTX dated on 2018-02-14: Vertex Phase 2 Study Of VX-150 Met Primary Endpoint Of Statistically Significant Improvement In SPID24 With VX-150 vs Placebo, Advances VX-128 Into Clinical Development

Financial news for VRTX dated on 2018-02-13: JMP Securities Maintains Market Outperform on Vertex Pharmaceuticals, Raises price target to \$211.00

Financial news for VRTX dated on 2018-02-13: Credit Suisse Maintains Outperform on Vertex Pharmaceuticals, Raises price target to \$196.00

Financial news for VRTX dated on 2018-02-12: Vertex Announces FDA Approved SYMDEKO

Financial news for VRTX dated on 2018-02-02: Morgan Stanley Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to \$200.00

Financial news for VRTX dated on 2018-02-01: Bank of America Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to \$197.00

Financial news for VRTX dated on 2018-02-01: BMO Capital Maintains Outperform on Vertex Pharmaceuticals, Raises Price Target to \$191.00

Financial news for VRTX dated on 2018-02-01: Barclays Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to \$200.00

Financial news for VRTX dated on 2018-02-01: 31 Stocks Moving In Thursday's Pre-Market Session

Financial news for VRTX dated on 2018-01-31: Vertex Reports Q4 Adj. EPS \$0.61 vs \$0.53 Est., Sales \$651.634M vs \$594.7M Est.

Financial news for VRTX dated on 2018-01-31: Vertex Reports Selected 2 Next-Gen Correctors, VX-659, VX-445 To Advance Into Phase 3 Development

Financial news for VRTX dated on 2018-01-31: Attention Biotech Investors: February PDUFA Catalysts Come Calling

Financial news for VRTX dated on 2018-01-31: Earnings Preview For Vertex Pharmaceuticals

Financial news for VRTX dated on 2018-01-31: Earnings Scheduled For January 31, 2018

Financial news for VRTX dated on 2018-01-29: AbbVie Shares Double In A Year; Leerink Moves To Sidelines

Financial news for VRTX dated on 2018-01-23: BofA Adds Allergan, Vertex Pharma To 'US 1' List

Financial news for VRTX dated on 2018-01-11: Vertex's Cystic Fibrosis Drug Given The Okay For Pediatric Use In Europe

Financial news for VRTX dated on 2018-01-10: Vertex Announces EU Approval for ORKAMBI in Children with Cystic Fibrosis Ages 6-11 with Two Copies of the F508del Mutation

Financial news for VRTX dated on 2018-01-08: How To Trade The JPMorgan Healthcare Conference

Financial news for VRTX dated on 2018-01-08: Adam Feuerstein Tweets: \$VRTX breakout, on triple combo CF: Want to take 2 programs into ph3, start 1H '18. Trial design not finalized but believe shorter endpoints 4 weeks or 8-12 weeks will be allowed. #JPM18

Financial news for VRTX dated on 2018-01-08: Vertex Pharma's Earnings Preview

Financial news for VRTX dated on 2018-01-08: 5 Stocks To Watch For January 8, 2018

Financial news for VRTX dated on 2018-01-08: Earnings Scheduled For January 8, 2018

Financial news for VRTX dated on 2018-01-05: BofA: The Biotech Sector Is In A 'Perfect Storm' For M&A

Financial news for VRTX dated on 2018-01-05: Bank of America Upgrades Vertex Pharmaceuticals to Buy

Financial news for VRTX dated on 2017-12-31: 10 Best Stocks Of 2017

Financial news for VRTX dated on 2017-12-24: Benzinga's Bulls & Bears: Looking Back, Looking Forward

Financial news for VRTX dated on 2017-12-22: The Companies That Led 2017's Biotech Rally

Financial news for VRTX dated on 2017-12-13: Deutsche Bank Initiates Coverage On Vertex Pharmaceuticals with Buy Rating, Announces \$175.00 Price Target

Financial news for VRTX dated on 2017-12-12: Vertex Pharma, CRISPR Therapeutics Report Will Co-Develop, Co-Commercialize CTX001 As CRISPR/Cas9 Gene Edited Treatment For Sickle Cell, B-Thalassemia

Financial news for VRTX dated on 2017-12-07: Vertex Reports Phase 3 Study Of KALYDECO Met Primary Endpoint And Showed Improvements Across Multiple Endpoints

Financial news for VRTX dated on 2017-11-10: Vertex Receives CHMP Positive Opinion for ORKAMBI for the Treatment of Children with Cystic Fibrosis Ages 6-11 with Two Copies of the F508del Mutation in the European Union

Financial news for VRTX dated on 2017-11-08: Credit Suisse Adjusts Its Top Picks List In A Record-Breaking Market

Financial news for VRTX dated on 2017-11-07: Credit Suisse Healthcare Conference Continues Today, Presenters Include: Walgreens, Vertex Pharmaceuticals, Laboratory Corp, Puma Biotech, Anthem, Alexion Pharma, Celgene, and Gilead

Financial news for VRTX dated on 2017-11-03: UPDATE: Vertex Highlights 'FDA Priority Review action date of February 28, 2018'

Financial news for VRTX dated on 2017-11-03: UPDATE: Vertex Says Data On Tezacaftor/Ivacaftor Combo 'showed significant improvements in lung function (ppFEV1) with a favorable safety profile across multiple patient groups'

Financial news for VRTX dated on 2017-11-03: Vertex Pharma Reports Phase 3 Studies Of Tezacaftor/Ivacaftor Combo Treatment In People With CF Ages 12+ Will Be Published In NEJM

Financial news for VRTX dated on 2017-10-25: Vertex Q3 Adj. EPS \$0.53 vs \$0.31 Est., Sales \$578.17M vs \$520.13M Est.

Financial news for VRTX dated on 2017-10-25: Earnings Scheduled For October 25, 2017

Financial news for VRTX dated on 2017-10-10: 5 Pharma & Biotech Stocks That Could Be Big Winners in Q3 Earnings

Financial news for VRTX dated on 2017-10-02: Benzinga's Bulls And Bears Of The Past Week: Netflix, Intel, Tesla And More

Financial news for VRTX dated on 2017-09-29: Benzinga's Top Upgrades, Downgrades For September 29, 2017

Financial news for VRTX dated on 2017-09-29: 3 Reasons To Like Vertex Pharma Shares

Financial news for VRTX dated on 2017-09-29: DA Davidson Initiates Coverage On Vertex Pharmaceuticals with Buy Rating, Announces \$200.00 Price Target

Financial news for VRTX dated on 2017-09-25: When Bull Markets Die: What To Watch For, What Stocks Could Be The First To Get Hit

Financial news for VRTX dated on 2017-09-21: Vertex's Rocky September Causes Vetr To Urge Sell

Financial news for VRTX dated on 2017-09-15: RBC Initiated Coverage On 33 Pharma/Biotech Cos.

Financial news for VRTX dated on 2017-09-11: STAT News' Adam Feuerstein Tweets '\$VRTX shuts down study of long-acting Kalydeco but insists development still on track'

Financial news for VRTX dated on 2017-09-11: STAT News Publishes 'Vertex shuts down study of long-acting Kalydeco but insists development still on track'

Financial news for VRTX dated on 2017-09-11: Morgan Stanley Healthcare Conference Begins Today, Presenters Include: Veeva Systems, Quorum Health, Neurocrine Biosciences, Vertex Pharma, Merck, Ocular Therapeutix, Biogen, Gilead, and Bristol-Myers

Financial news for VRTX dated on 2017-09-06: Vertex Pharmaceuticals Names Tom Graney SVP and CFO

Financial news for VRTX dated on 2017-08-24: Vertex Reports Acceptance Of Applications For Review Of Tezacaftor/Ivacaftor Combo Treatment Of Cystic Fibrosis By FDA, EMA

Financial news for VRTX dated on 2017-08-10: 13G/A Filing Shows T. Rowe Price Reporting 10.6% Stake In Vertex Pharmaceuticals

Financial news for VRTX dated on 2017-08-01: Vertex Announces That The FDA Approves KALYDECO

Financial news for VRTX dated on 2017-08-01: UPDATE: Vertex Raises FY17 KALYDECO Product Sales Outlook To \$770M-\$800M; Sees ORKAMBI Sales \$1.1B-\$1.3B; Total CF Product Sales Guidance \$1.87B-\$2.1B

Financial news for VRTX dated on 2017-08-01: Vertex Raises FY17 KALYDECO Product Sales

Financial news for VRTX dated on 2017-08-01: Vertex Pharma Reports FDA Approval Of KALYDECO For CF With Certain Residual Function Mutations

Financial news for VRTX dated on 2017-07-26: From Vertex Q2 Earnings Conference Call: Mgmt. Is Interested In Buying Early-Stage Assets In Disease Areas Consistent With CF

Financial news for VRTX dated on 2017-07-26: Vertex Pharmaceuticals Incorporated Reports Q2 Adj. EPS \$0.39 vs \$0.35 Est., Sales \$544.135M vs \$487.49M Est.

Financial news for VRTX dated on 2017-07-24: Concert Pharma Announces Termination of the HSR Act Waiting Period for CTP-656 Asset Purchase Agreement with Vertex

Financial news for VRTX dated on 2017-07-19: Mid-Afternoon Market Update: Scripps Rises On Report Of Merger Talks With Discovery; DryShips Shares Slide

Financial news for VRTX dated on 2017-07-19: 18 Biggest Mid-Day Gainers For Wednesday

Financial news for VRTX dated on 2017-07-19: Mid-Day Market Update: Crude Oil Up Over 1%; Cyclacel Pharma Shares Plummet

Financial news for VRTX dated on 2017-07-19: A Decade Of Sales Growth Lies Ahead For Vertex Pharmaceuticals

Financial news for VRTX dated on 2017-07-19: Hearing UBS Downgrades Vertex In Mid-Day Note

Financial news for VRTX dated on 2017-07-19: Mid-Morning Market Update: Markets Rise; Morgan Stanley Beats Q2 Estimates

Financial news for VRTX dated on 2017-07-19: 5 Biggest Price Target Changes For Wednesday

Financial news for VRTX dated on 2017-07-19: More Than 30% Upside Seen For Vertex Stock On The Heels Of Phase 2 Data

Financial news for VRTX dated on 2017-07-19: Benzinga's Top Upgrades, Downgrades For July 19, 2017

Financial news for VRTX dated on 2017-07-19: The Market In 5 Minutes

Financial news for VRTX dated on 2017-07-19: Vertex Pharmaceuticals Shares Up 27% In Pre-Market Following Strong Phase 1, 2 Data From 3 Different Triple Combo Regimens; String Of Analyst Upgrades

Financial news for VRTX dated on 2017-07-19: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for VRTX dated on 2017-07-19: Cowen & Co. Upgrades Vertex Pharmaceuticals to Outperform

Financial news for VRTX dated on 2017-07-19: Raymond James Upgrades Vertex Pharmaceuticals to Outperform

Financial news for VRTX dated on 2017-07-19: Janney Capital Upgrades Vertex Pharmaceuticals to Buy

Financial news for VRTX dated on 2017-07-19: Barclays Upgrades Vertex Pharmaceuticals to Overweight

Financial news for VRTX dated on 2017-07-18: STAT News' Adam Feuerstein Tweets 'Do not be surprised to see \$VRTX get FDA sign off to accelerate ph3s and secure faster approval for the triples.'

Financial news for VRTX dated on 2017-07-18: Vertex Pharma Shares To Resume Trade At 4:20 p.m. EDT

Financial news for VRTX dated on 2017-07-18: STAT News' Adam Feuerstein Tweets 'New \$VRTX drugs show dramatic gains for tough-to-treat cystic fibrosis patients --> <https://www.statnews.com/2017/07/18/vertex-cystic-fibrosis-results/> ... Triple combo data. Huge!'

Financial news for VRTX dated on 2017-07-18: UPDATE: Vertex Says 'All 3 triple combination regimens were generally well tolerated across the studies'

Financial news for VRTX dated on 2017-07-18: UPDATE: Vertex Says 'Phase 2 data showed mean absolute improvements in ppFEV1 of 9.7 and 12.0 percentage points for VX-152 and VX-440, respectively, in triple combination with tezacaftor and ivacaftor in F508del/Min patients'

Financial news for VRTX dated on 2017-07-18: Vertex Reports Phase 1, 2 Data From 3 Different Triple Combo Regimens In People With Cystic Fibrosis

Financial news for VRTX dated on 2017-07-18: Vertex Shares Halted News Pending

Financial news for VRTX dated on 2017-07-13: Vertex Announces Reimbursement Agreement in Italy for ORKAMBI, Which Treats the Underlying Cause of CF in People Ages 12 and Older with Two Copies of the F508del Mutation

Financial news for VRTX dated on 2017-07-11: Jefferies Initiates Coverage On Vertex Pharmaceuticals with Buy Rating, Announces \$155.00 Price Target

Financial news for VRTX dated on 2017-07-10: The Royalty-Amassing Strategy Of Royalty Pharma

Financial news for VRTX dated on 2017-07-07: 2 Stocks Up 50% In 2017 That Have Further Room For Upside

Financial news for VRTX dated on 2017-07-05: How Have The Best And Worst Stocks Of 2016 Performed In 2017?

Financial news for VRTX dated on 2017-07-03: 5 Hottest Stocks Of The First Half Of

2017

Financial news for VRTX dated on 2017-06-23: 2 Reasons Vertex Pharmaceuticals Just Got Upgraded

Financial news for VRTX dated on 2017-06-23: Benzinga's Top Upgrades, Downgrades For June 23, 2017

Financial news for VRTX dated on 2017-06-23: Needham Upgrades Vertex Pharmaceuticals to Buy

Financial news for VRTX dated on 2017-06-18: Vertex Pharmaceuticals Receives FDA Orphan Designation for Tezacaftor and Ivacaftor Combination Therapy

Financial news for VRTX dated on 2017-06-09: Vertex Announces Nine Presentations of Data on ORKAMBI, KALYDECO at ECFS Conference

Financial news for VRTX dated on 2017-06-02: Benzinga's Top Upgrades, Downgrades For June 2, 2017

Financial news for VRTX dated on 2017-06-02: Oppenheimer Upgrades Vertex Pharmaceuticals to Outperform

Financial news for VRTX dated on 2017-06-01: Vertex Announces Long-Term Reimbursement Agreement With Ireland For ORKAMBI, Future Cystic Fibrosis Medicines

Financial news for VRTX dated on 2017-05-24: Concert Pharma Reports Shareholder Approval of CTP-656 Asset Purchase Deal with Vertex

Financial news for VRTX dated on 2017-05-17: FDA Approves Vertex Pharma's KALYDECO

Financial news for VRTX dated on 2017-05-16: X-Chem, Vertex Enter into Multi-Target Genetic Disease Collaboration

Financial news for VRTX dated on 2017-04-27: Vertex Reaffirms FY17 Outlook for ORKAMBI, KALYDECO

Financial news for VRTX dated on 2017-04-27: Vertex Reports Q1 Adj. EPS \$0.41 vs \$0.40 Est.

Financial news for VRTX dated on 2017-04-17: Barron's Picks And Pans: Drug Stocks, Hanesbrands, Wabtec And More

Financial news for VRTX dated on 2017-04-07: Hearing Fresenius Said to Consider Offer for Akorn

Financial news for VRTX dated on 2017-04-07: Endo Int'l Shares Spike Into Positive Territory, Now Up 2%, Vertex Shares Also at Session Highs Up 2.3%

Financial news for VRTX dated on 2017-04-06: Stocks To Watch In Market Weakness

Financial news for VRTX dated on 2017-04-06: Your Cheat Sheet For Q1 Biotech Earnings

Financial news for VRTX dated on 2017-04-04: Benzinga's Option Alert Recap From April 4

Financial news for VRTX dated on 2017-04-04: Option Alert: Vertex Apr 110 Calls Sweep: 500 @ ASK \$4.796: 779 traded vs 1909 OI: Earnings 4/26 After Close (est) \$112.48 Re

Financial news for VRTX dated on 2017-03-30: Vetr Turns Bearish On Vertex After Drug Trial Success

Financial news for VRTX dated on 2017-03-30: Corbus Pharma's Positive Phase 2 Study: Safety First

Financial news for VRTX dated on 2017-03-29: Mid-Afternoon Market Update: RH Gains After Strong Q4 Results; Quorum Health Shares Plummet

Financial news for VRTX dated on 2017-03-29: 18 Biggest Mid-Day Gainers For Wednesday

Financial news for VRTX dated on 2017-03-29: Mid-Day Market Update: Crude Oil Up 1.5%; Alliqua Biomedical Shares Slide

Financial news for VRTX dated on 2017-03-29: Vertex Pharmaceuticals Leaps After Phase 3 Studies Meet Primary Endpoints

Financial news for VRTX dated on 2017-03-29: Benzinga's Top Upgrades, Downgrades For March 29, 2017

Financial news for VRTX dated on 2017-03-29: 22 Stocks Moving In Wednesday's Pre-Market Session

Financial news for VRTX dated on 2017-03-29: BMO Capital Upgrades Vertex Pharmaceuticals To Outperform

Financial news for VRTX dated on 2017-03-29: Vertex +17% Premarket @ \$105; Co Announced Tuesday 2 Phase 3 Studies of Tezacaftor/Ivacaftor Combo Treatment for CF Met Primary Endpoints

Financial news for VRTX dated on 2017-03-28: Vertex Pharma Resumes; Now \$101.02

Financial news for VRTX dated on 2017-03-28: Vertex Pharma Shares to Resume Trade at 6:40 p.m. EDT

Financial news for VRTX dated on 2017-03-28: Vertex Release Confirms 2 Phase 3 Studies of Tezacaftor/Ivacaftor Combo Treatment Met Primary Endpoints

Financial news for VRTX dated on 2017-03-28: Hearing Vertex Has Said Will File for US, Euro Approval of Kalydeco/Tezacaftor Combo in Q3'17

Financial news for VRTX dated on 2017-03-28: UPDATE: Vertex Says Adverse Events, Discontinuations with Kalydeco/Tezacaftor Combo Low, Similar to Placebo

Financial news for VRTX dated on 2017-03-28: Hearing Vertex Pharma Has Said CF Combo Therapy Significantly Improved Lung Function in Late Stage Trials; Shares Halted

Financial news for VRTX dated on 2017-03-20: Leerink Presents: Your 2017 Biopharma Catalyst Tracker

Financial news for VRTX dated on 2017-03-17: Benzinga's Top Upgrades, Downgrades For March 17, 2017

Financial news for VRTX dated on 2017-03-17: JMP Securities Upgrades Vertex Pharmaceuticals To Market Outperform

Financial news for VRTX dated on 2017-03-07: Wall Street's M&A Chatter From March 6

Financial news for VRTX dated on 2017-03-06: Mid-Afternoon Market Update: GoPro Slides Following Goldman Sachs Downgrade; TG Therapeutics Shares Spike Higher

Financial news for VRTX dated on 2017-03-06: 15 Biggest Mid-Day Gainers For Monday

Financial news for VRTX dated on 2017-03-06: Mid-Day Market Update: Dow Falls 80 Points; Concert Pharma Shares Spike Higher

Financial news for VRTX dated on 2017-03-06: Mid-Morning Market Update: Markets Open Lower; Deutsche Bank Plans to Raise Capital

Financial news for VRTX dated on 2017-03-06: 20 Stocks Moving In Monday's Pre-Market Session

Financial news for VRTX dated on 2017-03-06: A Peek Into The Markets: U.S. Stock Futures Edge Lower Ahead Of Factory Orders Data

Financial news for VRTX dated on 2017-03-06: Vertex to Acquire CTP-656 from Concert Pharmaceuticals For \$160M Cash And Potential \$90M In Milestones

Financial news for VRTX dated on 2017-02-24: Benzinga's Option Alert Recap From February 24

Financial news for VRTX dated on 2017-02-24: Option Alert: Vertex Mar 90.0 Calls: 900 @ ASK \$2.00: 1936 traded vs 1546 OI: Earnings 4/26 After Close (est) \$85.64 Ref

Financial news for VRTX dated on 2017-02-24: The Most Overpaid CEOs In S&P 500 Companies That Largely Underperformed The Market

Financial news for VRTX dated on 2017-01-25: Vertex Reports Q4 Adj EPS \$0.35 vs \$0.29 Est, Revenue \$454M vs \$453.4M Est

Financial news for VRTX dated on 2017-01-25: Earnings Scheduled For January 25, 2017

Financial news for VRTX dated on 2017-01-12: Watch These 8 Huge Call Purchases In Thursday Trade

Financial news for VRTX dated on 2017-01-11: Option Alert: Vertex Feb 95.0 Calls: 1400 @ ASK \$1.80: 1403 traded vs 22 OI: Earnings 1/25 After Close \$83.00 Ref

Financial news for VRTX dated on 2017-01-11: Merck KGaA, Darmstadt, Germany Licenses Four Oncology Research and Development Programs from Vertex; Vertex To Receive Upfront Payment \$230M

Financial news for VRTX dated on 2017-01-09: Vertex Shares Down 2.58%; Hearing JMP Securities Downgraded Co From Outperform To Market Perform

Financial news for VRTX dated on 2017-01-08: Vertex Pharmaceuticals Reports Preliminary Cystic Fibrosis Product Revenue of \$453M for Q4, \$1.68B for FY 2016

Financial news for VRTX dated on 2017-01-02: The Year-End Tax-Selling Strategy

Financial news for VRTX dated on 2016-12-30: Which Wall Street Firm Made The Best Stock Picks Of 2016?

Financial news for VRTX dated on 2016-12-28: Should You Be Buying 2016 Market Leaders Or Laggards Heading Into 2017?

Financial news for VRTX dated on 2016-12-27: 6 Worst Performing S&P 500 Stocks Of 2016

Financial news for VRTX dated on 2016-12-15: Oppenheimer Initiates Coverage On Vertex Pharmaceuticals at Perform

Financial news for VRTX dated on 2016-12-14: Despite A Downgrade, Vetr Still Bullish On Vertex

Financial news for VRTX dated on 2016-12-08: Biotech Stocks Convalescing After Wednesday's Trump-Inspired Biotech Selloff

Financial news for VRTX dated on 2016-12-05: 10 Stocks That Plummetered The Past Three Days On Increasing Volume

Financial news for VRTX dated on 2016-11-29: Barclays Downgrades 5 Biopharma Stocks, Upgrades Pfizer And Alexion

Financial news for VRTX dated on 2016-11-29: The Market In 5 Minutes: OPEC, Tiffany's And More Theranos Trouble

Financial news for VRTX dated on 2016-11-29: Baird Analyst Brian Skorney (In Response to Adam Feuerstein) Tweets: @adamfeuerstein This is after patients have already been on Orkambi, not newly started. Really shouldn't expect any additional improvement.

Financial news for VRTX dated on 2016-11-29: Adam Feuerstein Tweets: In \$NVLS study, notice alarmingly mediocre efficacy of Orkambi arm absolute change FEV1 0.97% at 12 wks. \$VRTX (caveat, cross trial comps.)

Financial news for VRTX dated on 2016-11-29: Adam Feuerstein @adamfeuerstein Tweet: In \$NVLS study, notice alarmingly mediocre efficacy of Orkambi arm absolute change FEV1 0.97% at 12 wks. \$VRTX (caveat, cross trial comps.)

Financial news for VRTX dated on 2016-11-29: Wall Street's M&A Chatter From November 28

Financial news for VRTX dated on 2016-11-29: Barclays Downgrades Vertex Pharmaceuticals to Equal-Weight

Financial news for VRTX dated on 2016-11-28: Vertex Pharmaceuticals Spokesperson Gives Statement Regarding Betaville M&A Report Involving Roche

Financial news for VRTX dated on 2016-11-28: Vertex Pharma Shares Edge Modestly Higher as Traders Passing Around Betaville Reporting Suggesting Roche Interest

Financial news for VRTX dated on 2016-11-07: Vertex Announces Positive Phase 3 Study of ORKAMBI in Children With Cystic Fibrosis Ages 6-11, Study Met Primary Endpoint With Statistically Significant Improvement In Absolute Change IN Lung Clearance Index

Financial news for VRTX dated on 2016-11-01: Benzinga's Top Downgrades

Financial news for VRTX dated on 2016-11-01: William Blair Downgrades Vertex Pharmaceuticals Incorporated - Common Stock to Market Perform

Financial news for VRTX dated on 2016-10-27: Vertex Reports Long-Term Data Showing ORKAMBI, KALYDECO Show Potential to Modify Progression of CF

Financial news for VRTX dated on 2016-10-26: 18 Stocks Moving In Wednesday's Pre-Market Session

Financial news for VRTX dated on 2016-10-26: 15 Stocks Which Plummetered Three Days On

Increasing Volume

Financial news for VRTX dated on 2016-10-25: Vertex Announces Planned Initiation of Phase 2 Studies Evaluating the Next-Generation Correctors VX-440 and VX-152 in Triple Combination Regimens to Treat the Underlying Cause of Cystic Fibrosis

Financial news for VRTX dated on 2016-10-25: Vertex Sees FY16 Rev. For ORKAMBI \$950-\$990M, KALYDECO Rev. Of \$685-\$705M

Financial news for VRTX dated on 2016-10-25: Vertex Reports Q3 EPS \$0.16 vs. Est. \$0.18, Rev. \$413.7M vs. Est. \$418.3M

Financial news for VRTX dated on 2016-10-24: Goldman Says These 25 Healthcare Stocks Are Immune To The Election

Financial news for VRTX dated on 2016-10-24: 7 Biggest Price Target Changes For Monday

Financial news for VRTX dated on 2016-10-24: Vertex Pharmaceuticals Relapses To A Neutral Rating At H.C. Wainwright

Financial news for VRTX dated on 2016-10-24: Benzinga's Top Downgrades

Financial news for VRTX dated on 2016-10-24: H.C. Wainwright Downgrades Vertex Pharmaceuticals Incorporated - Common Stock to Neutral, Lowers to \$85.00

Financial news for VRTX dated on 2016-10-14: UPDATE: Vertex Says Amended, Expanded Deal Provides Upfront Payment from CFFT of \$75M, Development Funding of Up to \$6M Annually

Financial news for VRTX dated on 2016-10-14: 8-K from Vertex Pharma Shows Amendment, Expansion of Research, Development, Commercialization Deal with CFFT to Clarify Terms of Relationship

Financial news for VRTX dated on 2016-09-28: 4 After-Hours Movers: Earnings, FDA Trials & Guide-Downs

Financial news for VRTX dated on 2016-09-28: Vertex Shares Falling 4% After Hours To \$85/Share

Financial news for VRTX dated on 2016-09-28: UPDATE: Vertex Cuts FY16 ORKAMBI Sales Guidance from \$1B-\$1.1B to \$950M-\$990M

Financial news for VRTX dated on 2016-09-28: Vertex Cuts FY16 ORKAMBI Sales Outlook

Financial news for VRTX dated on 2016-09-28: FDA Approves Vertex's Cystic Fibrosis Drug ORKAMBI For Use In Children

Financial news for VRTX dated on 2016-09-26: Vertex Pharmaceuticals ORKAMBI Cystic Fibrosis Drug's PDUFA Date Is Sept. 30

Financial news for VRTX dated on 2016-09-14: Technical Alert: Vertex Pharmaceuticals Trying To Find A Bottom

Financial news for VRTX dated on 2016-09-14: Hearing Vertex Defended At RBC

Financial news for VRTX dated on 2016-09-14: UPDATE: Vertex Pharma Comments Coming from Exec at Morgan Stanley Global Healthcare Conference

Financial news for VRTX dated on 2016-09-14: Vertex Pharma Shares Tumble Nearly \$10 as Hearing Co. Seeing 'Unexpected' Slowing of Prescription Refills During Jul. and Aug.

Financial news for VRTX dated on 2016-09-14: The Market In 5 Minutes: Huge FDA News, Major Mid-Week M&A

Financial news for VRTX dated on 2016-09-14: Can You Guess This Chart?

Financial news for VRTX dated on 2016-09-13: Benzinga's Top Initiations

Financial news for VRTX dated on 2016-09-13: Raymond James Initiates Coverage on Vertex Pharmaceuticals at Market Perform

Financial news for VRTX dated on 2016-08-15: Vertex Says VX-661 and ivacaftor Results Do Not Support Continuation Of The Study

Financial news for VRTX dated on 2016-08-15: Vertex Pharmaceuticals' Phase 3 Studies Offer Ample Opportunity For Upside

Financial news for VRTX dated on 2016-07-27: Vertex Reports Q2 EPS \$0.24 vs \$0.21 Est, Rev \$426M vs \$427.94M Est

Financial news for VRTX dated on 2016-07-27: Earnings Scheduled For July 27, 2016

Financial news for VRTX dated on 2016-07-06: UPDATE: Moderna Therapeutics to Receive \$40M Upfront, Made Up to \$20M Cash Payment, \$20M Convertible Note Investment, Has Potential for Up to Added \$275M in Milestone/Royalty Payments

Financial news for VRTX dated on 2016-07-06: Vertex Pharma, Moderna Therapeutics Report Establishment of Exclusive Collab Deal for Discovery, Development of mRNA Therapeutics for CF

Financial news for VRTX dated on 2016-06-16: Vertex Pharmaceuticals' Recuperation Will Continue, Vetr Crowd Says

Financial news for VRTX dated on 2016-06-14: Vetr Crowd Says Buy Vertex Pharmaceuticals

Financial news for VRTX dated on 2016-06-10: Downside Ahead For Biotech Stocks?

Financial news for VRTX dated on 2016-06-10: Vertex Reports Data For ivacaftor and lumacaftor/ivacaftor, Data Shows LT Impact Of KALYDECO Across Multiple Measures Of Disease

Financial news for VRTX dated on 2016-05-31: Vertex Gets FDA's Priority Review For SNDA For Its ORKAMBI

Financial news for VRTX dated on 2016-05-31: Vertex Pharmaceuticals Reports FDA Accepts sNDA For Review Of ORKAMBI, Target Date Of Sept. 30th

Financial news for VRTX dated on 2016-05-13: Short Interest Surges In Illumina And Vertex Pharmaceuticals

Financial news for VRTX dated on 2016-05-03: Vertex Pharmaceuticals Files for Potential Mixed Shelf; Size Not Disclosed

Financial news for VRTX dated on 2016-04-28: H.C. Wainwright: Vertex's Long-Term Value Is In The Pipeline

Financial news for VRTX dated on 2016-04-28: Short Sellers Dump Vertex, Load Up On Baxalta

Financial news for VRTX dated on 2016-04-28: 12 Stocks Moving In Thursday's Pre-Market Session

Financial news for VRTX dated on 2016-04-28: Goldman Sachs Downgrades Vertex Pharmaceuticals to Neutral, Lowers PT to \$88.00, Removed From Americas Buy List

Financial news for VRTX dated on 2016-04-27: Vertex Reports Q1 EPS \$0.09 vs. Est. \$0.29

Financial news for VRTX dated on 2016-04-27: Earnings Scheduled For April 27, 2016

Financial news for VRTX dated on 2016-04-18: Enterome Announces Has Signed Exclusive Global License Deal with Vertex Pharma for Research, Development, Commercialization of FimH Antagonists for Use in Treatment of IBD

Financial news for VRTX dated on 2016-04-16: After-Hours Recap: Active Rigs Count, Top Index Movers & More

Financial news for VRTX dated on 2016-04-13: Option Alert: VRTX Jul16 97.5 Calls: 1000 @ ASK \$3.90: 1002 traded vs 10 OI: Earnings 5/4 \$83.92 Ref

Financial news for VRTX dated on 2016-04-11: Credit Suisse Maintains Outperform on Vertex Pharmaceuticals, Lowers PT to \$112.00

Financial news for VRTX dated on 2016-04-07: After-Hours Recap: CarMax, Wynn, Relypsa, ConAgra, Ruby Tuesday & More

Financial news for VRTX dated on 2016-04-07: Benzinga's Top Initiations

Financial news for VRTX dated on 2016-04-07: BMO Capital Initiates Coverage on Vertex Pharmaceuticals at Market Perform

Financial news for VRTX dated on 2016-04-06: After-Hours Recap: Bed Bath & Beyond, Apollo, Valeant, eBay & More

Financial news for VRTX dated on 2016-04-04: The Stocks That Moved The S&P, Dow And

Nasdaq Today

Financial news for VRTX dated on 2016-03-31: Worst Stocks Of The First Quarter

Financial news for VRTX dated on 2016-03-28: The Stocks That Moved The S&P, Dow And Nasdaq Today

Financial news for VRTX dated on 2016-03-23: The Stocks That Moved The S&P, Dow And Nasdaq Today

Financial news for VRTX dated on 2016-03-10: The Stocks That Moved The S&P, Dow And Nasdaq Today

Financial news for VRTX dated on 2016-03-08: Vertex Receives Australian Approval for ORKAMBI(r) (lumacaftor/ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Two Copies of the F508del Mutation

Financial news for VRTX dated on 2016-03-02: The Stocks That Moved The S&P, Dow And Nasdaq Today

Financial news for VRTX dated on 2016-02-24: Vertex Reports Win of \$1M in Grants to 18 Non-Profit Organizations to Advance Initiatives for People Living with CF

Financial news for VRTX dated on 2016-02-13: Schroer: Biotech Will Turn Around

Financial news for VRTX dated on 2016-02-11: Oppenheimer Assumes Vertex Pharmaceuticals at Perform

Financial news for VRTX dated on 2016-02-08: Most Of Credit Suisse's Top Investment Ideas For 2016...In One Place

Financial news for VRTX dated on 2016-02-08: Analyst Sees 'No Reason' To Own MannKind

Financial news for VRTX dated on 2016-02-05: Here's Why Shares Of Vertex Pharmaceuticals Tumbled

Financial news for VRTX dated on 2016-02-05: Leerink Is Back On Board The Biotech Train

Financial news for VRTX dated on 2016-02-05: Vertex Pharma -4.6% Premarket @\$87.50 Following Announcement of CRL by FDA

Financial news for VRTX dated on 2016-02-05: Vertex Receives Complete Response Letter from U.S. FDA for Use of KALYDECO in People with Cystic Fibrosis Ages 2 and Older

Financial news for VRTX dated on 2016-02-05: Leerink Swann Initiates Coverage on Vertex Pharmaceuticals at Outperform

Financial news for VRTX dated on 2016-02-01: Jefferies Upgrades Vertex Pharmaceuticals to Buy, Lowers to \$120.00

Financial news for VRTX dated on 2016-01-28: Street Likes Incyte & Vertex After Drug Trial, Earnings Update

Financial news for VRTX dated on 2016-01-28: Mid-Morning Market Update: Markets Open Higher; Ford Tops Q4 Views

Financial news for VRTX dated on 2016-01-27: Vertex Earlier Affirmed FY16 KALYDECO Sales \$670M-\$690M

Financial news for VRTX dated on 2016-01-27: Vertex Reports Q4 EPS \$0.17 vs. Est. \$0.17, Rev. \$417.935M vs. Est. \$406.3M

Financial news for VRTX dated on 2016-01-27: Earnings Scheduled For January 27, 2016

Financial news for VRTX dated on 2016-01-26: Vertex Pharma Reports Health Canada Approves ORKAMBI For Underlying Cause Of Cystic Fibrosis 12 Years And Older

Financial news for VRTX dated on 2016-01-20: Credit Suisse Bullish On Most Big Pharma Names

Financial news for VRTX dated on 2016-01-19: Credit Suisse Initiates Coverage on Vertex Pharmaceuticals at Outperform, Announces \$151.00 PT

Financial news for VRTX dated on 2015-12-01: Benzinga's Top Initiations

Financial news for VRTX dated on 2015-12-01: Stifel: Buy Vetrex, Checks Predict Strong Orkambi Launch

Financial news for VRTX dated on 2015-12-01: Stifel Nicolaus Initiates Coverage on Vertex Pharmaceuticals at Buy, Announces \$125.00 PT

Financial news for VRTX dated on 2015-11-23: Vertex Appoints Michael J. Parini as EVP and Chief Legal Officer

Financial news for VRTX dated on 2015-11-20: Vertex Receives EU Approval for ORKAMBI(r) (lumacaftor/ivacaftor)

Financial news for VRTX dated on 2015-11-18: Early Global News: ON Semiconductor To Buy Fairchild, Stratascys And Autos, Google Maps Vs. Yelp

Financial news for VRTX dated on 2015-11-18: Vertex Receives Two EU Approvals for KALYDECO for Cystic Fibrosis

Financial news for VRTX dated on 2015-10-30: Details in Vertex Pharma 10-Q Confirms DoJ Subpoena

Financial news for VRTX dated on 2015-10-30: Shares of Vertex Pharma Indicated Lower Following Chatter Co. Received DoJ Subpoena During Q3

Financial news for VRTX dated on 2015-10-30: Benzinga's Top Upgrades

Financial news for VRTX dated on 2015-10-30: H.C. Wainwright Upgrades Vertex Pharmaceuticals to Buy, Raises PT to \$155.00

Financial news for VRTX dated on 2015-10-29: Morning Market Gainers

Financial news for VRTX dated on 2015-10-29: Benzinga's Top #PreMarket Gainers

Financial news for VRTX dated on 2015-10-28: Vertex Raises FY15 KALYDECO Sales Outlook from \$575M-\$590M to \$605M-\$620M

Financial news for VRTX dated on 2015-10-28: Vertex Pharmaceuticals Incorporated Reports Q3 Loss \$0.13 Vs Est Loss \$0.25, Sales \$310M Vs Est \$245.97M

Financial news for VRTX dated on 2015-10-27: Biotech ETFs: Buy, Buy, Buy?

Financial news for VRTX dated on 2015-10-20: Oppenheimer Incrementally More Bullish on Gilead, Remains Cautious On Vertex

Financial news for VRTX dated on 2015-10-19: Cowen: In Biotech Earnings We Trust

Financial news for VRTX dated on 2015-10-08: UPDATE: Vertex Says Two Next-Gen Correctors to Enter Clinical Development in Nov; Studies of Triple Combo Planned for '16

Financial news for VRTX dated on 2015-10-08: Vertex Pharma Announces Progress in Development Efforts to Treat Cause of Cystic Fibrosis

Financial news for VRTX dated on 2015-10-07: Vertex Announces sNDA for Use of KALYDECO Accepted for Priority Review

Financial news for VRTX dated on 2015-10-02: Benzinga's Top Upgrades

Financial news for VRTX dated on 2015-10-02: Morgan Stanley On Big Biotech: Upgrades, Pfizer, Vertex, Alexion, Cuts Gilead, Valeant

Financial news for VRTX dated on 2015-10-02: Morgan Stanley Upgrades Vertex Pharmaceuticals to Overweight, Raises PT to \$148.00

Financial news for VRTX dated on 2015-09-29: Why Argus Upgraded Vertex Pharma To Buy Last Week

Financial news for VRTX dated on 2015-09-28: Argus Research Upgrades Vertex Pharmaceuticals to Buy, Maintains \$126.00 PT

Financial news for VRTX dated on 2015-09-25: Vertex Announces Received CHMP Positive Opinion for ORKAMBI, KALYDECO in EU

Financial news for VRTX dated on 2015-09-14: Amgen And Biogen Lead Short Interest Surge In Biotechs

Financial news for VRTX dated on 2015-09-14: Vertex Pharma's Orkambi Gives It Huge Potential, Says Barclays

Financial news for VRTX dated on 2015-09-14: Morning Market Gainers

Financial news for VRTX dated on 2015-09-14: Benzinga's Top Upgrades

Financial news for VRTX dated on 2015-09-14: Benzinga's Top #PreMarket Gainers

Financial news for VRTX dated on 2015-09-14: Barclays Favorite Biotech Names For Year End Balance Are Gilead, Vertex, Medivation

Financial news for VRTX dated on 2015-09-14: US Stock Futures Signal Higher Start On Wall Street

Financial news for VRTX dated on 2015-09-14: Barclays Upgrades Vertex Pharmaceuticals to Overweight, Raises PT to \$150.00

Financial news for VRTX dated on 2015-08-27: Biogen And Gilead Sciences Catch The Eye Of Short Sellers

Financial news for VRTX dated on 2015-08-26: 4 Biotechs Piper Jaffray Is Buying On The Pullback

Financial news for VRTX dated on 2015-07-29: Vertex Reports Q2 Loss \$0.78 Vs Est Loss \$0.58, Sales \$166.1M Vs Est \$149.70M, Kalydeco Revs TO Be \$575-\$590M In 2015

Financial news for VRTX dated on 2015-07-28: Is More M&A On The Way For Large-Cap Biotechs?

Financial news for VRTX dated on 2015-07-10: CNBC's Meg Tirrel Speculates About Gilead's New Acquisiton

Financial news for VRTX dated on 2015-07-07: Baird And Piper Jaffray Love Vertex: Here's Why

Financial news for VRTX dated on 2015-07-06: Vertex Pharma Is 'Hyped,' H.C. Wainwright Sees 35% Downside

Financial news for VRTX dated on 2015-07-05: Evercore ISI Analyst Gives Highlights From Vertex's Orkambi Call

Financial news for VRTX dated on 2015-07-03: CNBC's Stock Pops & Drops From July 2

Financial news for VRTX dated on 2015-07-02: Shares of Vertex Pharma Down Sharply from Session High at \$132, Now Trading at ~\$128.80, Up Less Than 2% for Session

Financial news for VRTX dated on 2015-07-02: UPDATE: Vertex Shares Trading Up 3.5% from Wednesday's Close

Financial news for VRTX dated on 2015-07-02: Shares of Vertex Resume Trade; Now Trading Slightly Lower from Halt

Financial news for VRTX dated on 2015-07-02: Shares of Vertex to Resume Trade at 3 p.m. EDT

Financial news for VRTX dated on 2015-07-02: Vertex Shares Leap On FDA Approval For Cystic Fibrosis Combo ORKAMBI

Financial news for VRTX dated on 2015-07-02: ORKAMBI Price At \$259K/Year, Est Was For \$230-\$250K - Vertex Pharma Announces On Conf. Call

Financial news for VRTX dated on 2015-07-02: Vertex Pharma Execs Currently Discussing ORKAMBI on Conference Call

Financial news for VRTX dated on 2015-07-02: The Cystic Fibrosis Foundation Issues Release Celebrating FDA Approval of Lumacaftor/Ivacaftor Combo Drug ORKAMBI

Financial news for VRTX dated on 2015-07-02: UPDATE: Vertex Will Host Conference Call at 2:15 p.m. EDT to Offer More Info on Approval of ORKAMBI

Financial news for VRTX dated on 2015-07-02: UPDATE: Vertex Release Confirms FDA Approval of ORKAMBI

Financial news for VRTX dated on 2015-07-02: Vertex Release Confirms FDA Approval of ORKAMBI

Financial news for VRTX dated on 2015-07-02: Goldman Comments On Vertex Pharmaceuticals Following FDA Approval

Financial news for VRTX dated on 2015-07-02: Goldman on Vertex: We Await Orkambi Pricing Details, Expect To Be On Par With Kalydeco (\$312K/Yr) Given Strong Secondary Endpoint And Historical Analysis Of Orphan Drug Pricing

Financial news for VRTX dated on 2015-07-02: The Street's Adam Feuerstein Recently Highlighting Pricing for Vertex

Financial news for VRTX dated on 2015-07-02: Adam Feuerstein Tweets: 'We now wait for Orkambi price. \$VRTX'

Financial news for VRTX dated on 2015-07-02: Vertex Wins US Approval For Cystic Fibrosis Combo Orkambi

Financial news for VRTX dated on 2015-07-02: Vertex Shares Halted News Pending

Financial news for VRTX dated on 2015-06-26: Benzinga's Top #PreMarket Gainers

Financial news for VRTX dated on 2015-06-18: Sangeeta N. Bhatia, M.D., Ph.D., Joins Vertex Board of Directors

Financial news for VRTX dated on 2015-06-11: Vertex Pharma Offers Data Presentations at ECFS Conference: TRAFFIC, TRANSPORT Extension Study of Lumacaftor Im Combo with Ivacaftor Showed Improvements

Financial news for VRTX dated on 2015-06-08: Vertex Pharmaceuticals Will Outperform, Has 'Competitive Edge,' JMP Says

Financial news for VRTX dated on 2015-06-04: Vertex Announces Collaboration with Parion Sciences to Develop ENaC Inhibitors in CF, Pulmonary Diseases

Financial news for VRTX dated on 2015-05-17: Vertex Pharmaceuticals Announces NEJM Publishes Data from Two Phase 3 Studies of ORKAMBITM

Financial news for VRTX dated on 2015-05-13: JPMorgan, Canaccord Confident That Vertex's CF Drug Will Get FDA Approval

Financial news for VRTX dated on 2015-05-13: Vertex Shares Rally As FDA Panel Backs Orkambi; HC Wainwright Analyst Offers Thoughts

Financial news for VRTX dated on 2015-05-13: Morning Market Gainers

Financial news for VRTX dated on 2015-05-13: Benzinga's Top #PreMarket Gainers

Financial news for VRTX dated on 2015-05-12: Tuesday's After-Hours Movers: Vertex Pharmaceuticals, Orexigen Therapeutics And More

Financial news for VRTX dated on 2015-05-12: Shares of Vertex to Resume Trade at 4:45 p.m. EDT

Financial news for VRTX dated on 2015-05-12: Vertex Release Confirms FDA Panel Voted 12-1 to Recommend Approval of ORKAMBI for Treatment of Cystic Fibrosis

Financial news for VRTX dated on 2015-05-12: Vertex's Orkambi Gains Backing Of U.S. FDA Advisers

Financial news for VRTX dated on 2015-05-12: FDA Advisory Panel Vote Inconclusive on Whether Vertex's Lumacaftor Contributes Positively to Orkambi's Effectiveness

Financial news for VRTX dated on 2015-05-12: UPDATE: Shares of Vertex Currently Halted Up ~0.75% to \$125.05 Ahead of FDA Advisory Panel to Review Cystic Fibrosis Combo

Financial news for VRTX dated on 2015-05-12: Vertex Pharma Shares Halted News Pending

Financial news for VRTX dated on 2015-05-09: Why Fears Of Biotech Being Overvalued Are Unwarranted

Financial news for VRTX dated on 2015-05-08: Vertex Shares Moving Lower as FDA Issues Results of May 12 Panel Related to Ivacaftor/Lumacaftor Combo

Financial news for VRTX dated on 2015-04-30: Is Gilead Sciences About To Buy Vertex For \$45 Billion?

Financial news for VRTX dated on 2015-04-29: Vertex Pharma Reports Q1 Adj. Loss of \$0.62/Share vs Loss of \$0.75/Share Est., Sales \$138.5M vs \$142.4M Est.

Financial news for VRTX dated on 2015-04-29: What's Wall Street Been Saying About Gilead Lately?

Financial news for VRTX dated on 2015-04-29: Veritex Holdings Reports Q1 EPS \$0.19 Vs Est \$0.17

Financial news for VRTX dated on 2015-04-28: 3 Biotech Stocks With Rising Short

Interest

Financial news for VRTX dated on 2015-04-27: Oppenheimer Assumes Vertex Pharmaceuticals at Perform

Financial news for VRTX dated on 2015-04-21: Benzinga's M&A Chatter for Tuesday April 21, 2015

Financial news for VRTX dated on 2015-04-21: Gilead-Vertex Deal Has 'Low Probability' Of Happening, RBC Capital Says

Financial news for VRTX dated on 2015-04-21: Adam Feuerstein @adamfeuerstein Tweet: Ackman could be interviewed on @CNBC multiple times across many shows to promote/pump his \$GILD position.

Financial news for VRTX dated on 2015-04-21: Should Gilead Buy Vertex?

Financial news for VRTX dated on 2015-04-21: Hearing RBC Says Probability of Gilead Buying Vertex is Low

Financial news for VRTX dated on 2015-04-21: RBC Analyst Saying Gilead and Vertex Deal Is A 'pretty low probability'

Financial news for VRTX dated on 2015-04-21: Tweet, Rumor And Bernstein Fueling Rallies In Gilead Sciences, Vertex Pharmaceuticals

Financial news for VRTX dated on 2015-04-21: Hearing Unconfirmed Market Chatter of Ackman \$2B Stake in Gilead; Ackman Said to Push for Acquisition of Vertex

Financial news for VRTX dated on 2015-04-21: Bernstein: It's Time For Gilead To Pull The Trigger On This Acquisition

Financial news for VRTX dated on 2015-04-21: Adam Feuerstein @adamfeuerstein Tweet: \$GILD Should Buy \$VRTX for \$45B Now, Analyst Says thestreet.com/story/13119465... via @TheStreet

Financial news for VRTX dated on 2015-04-10: Is This Stock A Vertex Pharma Clone?

Financial news for VRTX dated on 2015-04-10: Benzinga's Top Initiations

Financial news for VRTX dated on 2015-04-10: Canaccord Genuity Initiates Vertex Pharmaceuticals At Buy

Financial news for VRTX dated on 2015-04-10: Canaccord Genuity Initiates Coverage on Vertex Pharmaceuticals at Buy, Announces \$150.00 PT

Financial news for VRTX dated on 2015-03-26: Is It Closing Time At The Biotech Bar?

Financial news for VRTX dated on 2015-03-24: Morgan Stanley Talks New Vertex Data

Financial news for VRTX dated on 2015-03-24: Vertex Treatment May Have High Risk of Failure, Analyst Suggests

Financial news for VRTX dated on 2015-03-23: Deutsche Bank: Vertex Pharma's Disappointing VX-661 Trial Results Isn't The End

Financial news for VRTX dated on 2015-03-23: ICYMI: Pharmaceutical Stocks Are Moving Big On Monday

Financial news for VRTX dated on 2015-03-23: Deutsche Bank Analyst Suggests Buy Vertex Shares on Weakness, Reiterates Buy, \$155 Price Target

Financial news for VRTX dated on 2015-03-23: Morning Market Losers

Financial news for VRTX dated on 2015-03-23: Benzinga's Top #PreMarket Losers

Financial news for VRTX dated on 2015-03-23: Vertex Reports Data from 12-Week Phase 2 Safety Study of VX-661 in Combo with Ivacaftor: Shows Combo Generally Well Tolerated

Financial news for VRTX dated on 2015-03-20: Maxim: Our Vertex Pharma Thesis Is Unchanged

Financial news for VRTX dated on 2015-03-18: Vertex Recieves FDA Approval Of KALYDECO For Cystic Fibrosis In Children From 2-5 Years Old With Special Mutation In CFTR Gene

Financial news for VRTX dated on 2015-03-13: Short Sellers Still Attracted To Biotech Stocks

Financial news for VRTX dated on 2015-03-09: UPDATE: Veritex Holdings to Acquire IBT

Bancorp for ~1.185M Shares of Veritex Stock, \$4M in Cash

Financial news for VRTX dated on 2015-03-05: Biotech M&A Outlook Boosted By AbbVie Deal, Says This RBC Analyst

Financial news for VRTX dated on 2015-02-26: Short Sellers Come Back To Biotech Stocks

Financial news for VRTX dated on 2015-02-24: UPDATE: Hearing Now that Vertex is Not Interested in PTC Therapeutics, They are Interested in a Cystic Fibrosis Play, PTC is Not a Major Cystic Fibrosis Play

Financial news for VRTX dated on 2015-02-24: Hearing Unconfirmed Market Chatter of Vertex Interest in PTC Therapeutics

Financial news for VRTX dated on 2015-02-12: Short Sellers Retreat From Biotech Stocks

Financial news for VRTX dated on 2015-01-29: Baird Releases Comments After Vertex Earnings Call

Financial news for VRTX dated on 2015-01-29: Maxim Downgrades Vertex Pharmaceuticals After Earnings

Financial news for VRTX dated on 2015-01-29: Morning Market Losers

Financial news for VRTX dated on 2015-01-29: Benzinga's Top #PreMarket Losers

Financial news for VRTX dated on 2015-01-28: Vertex Pharmaceuticals Beats Q4 Revenue Expectations

Financial news for VRTX dated on 2015-01-28: Vertex Pharma Reported Q4 Adj. Loss of \$0.55/Share

Financial news for VRTX dated on 2015-01-28: Vertex Reports Q4 Loss Of -0.74 Vs. Est. Loss Of \$0.65

Financial news for VRTX dated on 2015-01-28: Earnings Scheduled For January 28, 2015

Financial news for VRTX dated on 2015-01-26: 5 Big Biotech Earnings Releases To Watch This Week

Financial news for VRTX dated on 2015-01-20: Vertex Pharma Says Horton Now Acting As Special Counsel To CEO

Financial news for VRTX dated on 2015-01-14: Vertex CEO On Company's New Cystic Fibrosis Drug, Pricing Strategy

Financial news for VRTX dated on 2015-01-12: Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 1

Financial news for VRTX dated on 2015-01-11: Vertex Sees Kalydeco FY Revenue \$560M-\$580M

Financial news for VRTX dated on 2015-01-09: Adam Feuerstein @adamfeuerstein Tweet: \$GILD Buying \$VRTX Among Bold Biotech Stock Predictions for 2015 thestreet.com/story/13006004... @dsobek peers into his Cajun crystal ball...

Financial news for VRTX dated on 2015-01-06: J.P Morgan Just Chimed In With Ratings On Biotech Stocks

Financial news for VRTX dated on 2015-01-06: UPDATE: Barclays Capital Initiates Coverage On Vertex Pharmaceuticals On Leading Position In CF Market

Financial news for VRTX dated on 2015-01-06: Barclays Initiates Coverage on Vertex Pharmaceuticals at Equal-weight, Announces \$120.00 PT

Financial news for VRTX dated on 2015-01-05: BTIG Initiates Coverage On Vertex Pharmaceuticals, Notes Company's Cystic Fibrosis Therapies

Financial news for VRTX dated on 2015-01-05: BTIG Research Initiates Coverage on Vertex Pharmaceuticals at Buy, Announces \$200.00 PT

Financial news for VRTX dated on 2014-12-29: U.S. Food and Drug Administration Approves KALYDECO(r) (ivacaftor) for Use in People with Cystic Fibrosis Ages 6 and Older Who Have the R117H Mutation

Financial news for VRTX dated on 2014-12-29: U.S. Food and Drug Administration Approves KALYDECO for Use in People with Cystic Fibrosis Ages 6 and Older Who Have

the R117H Mutation

Financial news for VRTX dated on 2014-12-26: William Blair's Top BioPharma Stock Picks For Q1 2015

Financial news for VRTX dated on 2014-12-22: Benzinga's Top #PreMarket Losers

Financial news for VRTX dated on 2014-12-15: Vertex Reports Naming of David Altshuler as Exec VP, Global Research, Chief Scientific Officer

Financial news for VRTX dated on 2014-12-11: Don't Overlook Mid-Cap Stocks

Financial news for VRTX dated on 2014-12-03: Great News For Biogen, But What's Next For The Stock?

Financial news for VRTX dated on 2014-11-19: Adam F Says Royalty Pharma's \$3.3B Deal for Rights to Cystic Fibrosis Drugs is Bullish for Vertex

Financial news for VRTX dated on 2014-11-19: Royalty Pharma Reports Purchase of Acquisition of Royalties on Vertex Pharma's CF Treatments Owned by CFFT for \$3.3B in Cash

Financial news for VRTX dated on 2014-11-05: Vertex Submits Applications in US, Europe for Approval of Lumacaftor in Combination with Ivacaftor for People with Cystic Fibrosis Who Have Two Copies of F508del Mutation

Financial news for VRTX dated on 2014-11-05: Vertex Submits Applications In The U.S. And Europe For Approval Of Lumacaftor In Combination With Ivacaftor

Financial news for VRTX dated on 2014-10-29: JMP Securities Maintains Market Perform on Vertex Pharmaceuticals Incorporated, Raises PT to \$133.00

Financial news for VRTX dated on 2014-10-28: Vertex Pharmaceuticals Incorporated Reports Q3 EPS of \$(0.37) vs \$(0.63) Est; Revenue of \$179.0M vs \$146.95M Est

Financial news for VRTX dated on 2014-10-28: Vertex Energy Agrees to Acquire Substantially All Assets of Heartland Group Holdings -8-K

Financial news for VRTX dated on 2014-10-28: Earnings Scheduled For October 28, 2014

Financial news for VRTX dated on 2014-10-21: FDA Advisory Committee Recommends Approval of KALYDECO

Financial news for VRTX dated on 2014-10-21: Vertex Has Won FDA Panel Vote for Kalydeco, Vote for Safety Was 14-1 In Favor, Vote for Approval 13-2

Financial news for VRTX dated on 2014-10-21: FDA Advisory Panel Has Voted Vertex's Kalydeco is Safe for R117H Mutation

Financial news for VRTX dated on 2014-10-17: FDA Reviews Vertex Pharma's KALYDECO for CF with R117H Mutation, Publishes Report for Oct. 21 Panel Meeting

Financial news for VRTX dated on 2014-10-14: Hearing Bank of America Merrill Lynch Cautious on Vertex

Financial news for VRTX dated on 2014-10-14: Bank Of America Is Impressed By Takeaways From Vertex Pharmaceuticals Conference Call

Financial news for VRTX dated on 2014-10-13: UPDATE: Piper Jaffray Upgrades Vertex Pharmaceuticals Ahead Of Expected Combination Approvals

Financial news for VRTX dated on 2014-10-13: Big Swings in Biotech Short Interest

Financial news for VRTX dated on 2014-10-13: Benzinga's Top Upgrades

Financial news for VRTX dated on 2014-10-13: Piper Jaffray Upgrades Vertex Pharmaceuticals To Overweight

Financial news for VRTX dated on 2014-10-13: Piper Jaffray Upgrades Vertex Pharmaceuticals Incorporated to Overweight, Raises PT to \$125.00

Financial news for VRTX dated on 2014-10-09: Vertex Reviews Recent Progress and Announces Upcoming Milestones in the Development of Multiple Combinations of Medicines that Target the Underlying Cause of Cystic Fibrosis

Financial news for VRTX dated on 2014-10-02: Guggenheim Securities Initiates Coverage on Vertex Pharmaceuticals Incorporated at Buy, Announces \$147.00 PT

Financial news for VRTX dated on 2014-10-01: H.C. Wainwright Highlights Its Top Picks

Ahead Of NACFC 2014

Financial news for VRTX dated on 2014-09-25: Fast Money Picks For September 26 - Pfizer Inc., The Dow Chemical Company And More

Financial news for VRTX dated on 2014-09-24: Stocks Hitting 52-Week Highs

Financial news for VRTX dated on 2014-09-22: These 3 Biotech Stocks Just Hit New Highs

Financial news for VRTX dated on 2014-09-19: Midday Gainers From September 19 - Alibaba Group Holding Ltd, Concur Technologies, Inc. And More

Financial news for VRTX dated on 2014-09-16: Deutsche Bank Boosts Target on Vertex Pharma from \$103 to \$127, Buy Maintained

Financial news for VRTX dated on 2014-09-08: Benzinga's Top Upgrades

Financial news for VRTX dated on 2014-09-08: Goldman Sachs Upgrades Vertex Pharmaceuticals To Buy

Financial news for VRTX dated on 2014-09-08: Goldman Sachs Upgrades Vertex Pharmaceuticals Incorporated to Buy, Raises PT to \$131.00

Financial news for VRTX dated on 2014-07-31: Vertex Receives EC Approval for KALYDECO in Eight Non-G551D Gating Mutations

Financial news for VRTX dated on 2014-07-30: Vertex Pharmaceuticals: Analysts Offer Insight On Business Developments

Financial news for VRTX dated on 2014-07-29: Vertex Pharma Reports Q2 Loss of \$0.68/Share, Sales \$138.4M; Reaffirms FY Outlook

Financial news for VRTX dated on 2014-07-23: Vertex Is Poised For An Earnings Breakout

Financial news for VRTX dated on 2014-07-08: Oppenheimer Initiates Coverage on Vertex Pharmaceuticals Incorporated at Market Perform

Financial news for VRTX dated on 2014-06-30: Vertex Announces sNDA to FDA for Kaldeco

Financial news for VRTX dated on 2014-06-30: Vertex Shares Edge Higher as FDA Indicates Orphan Drug Designation for lumacaftor and ivacaftor

Financial news for VRTX dated on 2014-06-27: Vertex Announces Positive Opinion For Kalydeco From European CHMP

Financial news for VRTX dated on 2014-06-25: Adam Feuerstein Tweet: Mad About Missing \$VRTX Big Move? Don't Be, The Stock Is Still Undervalued --> thestreet.com/story/12756325

Financial news for VRTX dated on 2014-06-25: Analyst Concerns On Vertex's Approved Drug

Financial news for VRTX dated on 2014-06-25: Benzinga's Top Downgrades

Financial news for VRTX dated on 2014-06-25: HC Wainwright Downgrades Vertex Pharmaceuticals Incorporated to Neutral

Financial news for VRTX dated on 2014-06-24: Consumer Confidence And Housing Data Take A Back-Seat To Markets

Financial news for VRTX dated on 2014-06-24: Utility Sector Rises; Elizabeth Arden Shares Slide Over 3.6%

Financial news for VRTX dated on 2014-06-24: UBS Analyst Comments On Vertex's Combination Regimen

Financial news for VRTX dated on 2014-06-24: Micron Gains On Upbeat Earnings; Elizabeth Arden Shares Slide

Financial news for VRTX dated on 2014-06-24: Deutsche Bank Reiterates Buy on Vertex Pharmaceuticals Following Press Release

Financial news for VRTX dated on 2014-06-24: Bernstein Weighs In On Vertex Move

Financial news for VRTX dated on 2014-06-24: Benzinga's Volume Movers

Financial news for VRTX dated on 2014-06-24: Mid-Morning Market Update: Markets

Mostly Higher; Walgreen Profit Misses Estimates

Financial news for VRTX dated on 2014-06-24: Stocks Hitting 52-Week Highs

Financial news for VRTX dated on 2014-06-24: Morning Market Movers

Financial news for VRTX dated on 2014-06-24: Why Is Vertex Pharmaceuticals Up More Than 50 Percent?

Financial news for VRTX dated on 2014-06-24: Benzinga's Top #PreMarket Gainers

Financial news for VRTX dated on 2014-06-24: Vertex Pharma Shares Resume Trade, Now Up Nearly 43%

Financial news for VRTX dated on 2014-06-24: Shares of Vertex Pharma to Resume Trade at 7:30 a.m. EDT

Financial news for VRTX dated on 2014-06-24: UPDATE: Vertex Pharma Announces Primary Endpoint Was Met for Lumacaftor Study

Financial news for VRTX dated on 2014-06-24: Vertex Says Two 24-Week Phase 3 Studies of Lumacaftor in Combo with Ivacaftor Met Primary Endpoint, Statistically Significant Improvements

Financial news for VRTX dated on 2014-06-24: Vertex Pharma Halted News Pending

Financial news for VRTX dated on 2014-06-18: J&J's Janssen Announces License Deal with Vertex to Develop Novel Treatment for Influenza A

Financial news for VRTX dated on 2014-06-18: Vertex Licenses VX-787 to Janssen Pharma, Vertex to Receive \$30M Upfront

Financial news for VRTX dated on 2014-06-16: Vertex Reports Signed Letter of Intent to Enable Public Reimbursement of KALYDECO in Canada

Financial news for VRTX dated on 2014-06-16: Vertex Shares Hit Hard On Trial Concerns

Financial news for VRTX dated on 2014-06-16: Mid-Day Market Movers For Monday, June 16, 2014

Financial news for VRTX dated on 2014-06-16: Benzinga's Top #PreMarket Losers

Financial news for VRTX dated on 2014-06-12: Vertex Releases New Data on KALYDECO, Says Shows Loss of Lung Function Reduced by Half Over Three Years

Financial news for VRTX dated on 2014-06-04: Vertex Pharmaceuticals Announces Positive Results From First Two Week of Cystic Fibrosis Treatment

Financial news for VRTX dated on 2014-05-20: Option Alert: Vertex Jul \$70/\$100 Call Spread; 2,994 Spread Trade; Currently \$65.95

Financial news for VRTX dated on 2014-05-01: Vertex Pharmaceuticals Incorporated Reports Q1 EPS of \$(1.00) vs \$(0.68) Est

Financial news for VRTX dated on 2014-04-25: FDA Reports Orphan Drug Designation for Vertex's CF Treatment - Bloomberg

Financial news for VRTX dated on 2014-04-09: Option Alert: Jun \$75 Call; 2,500 Contracts Traded vs 71 OI; Currenlty \$66.96

Financial news for VRTX dated on 2014-04-08: Express Scripts Reports Spending on Hepatitis C Medications in US to Rise 1,800% by 2016

Financial news for VRTX dated on 2014-02-21: FDA Approves Vertex's Kalydeco for Use in Eight Added Mutations

Financial news for VRTX dated on 2014-02-21: Adam Feuerstein Tweet:\$VRTX Swaps Endpoints in Key Cystic Fibrosis Studies --> thetstreet.com/story/12438631

Financial news for VRTX dated on 2014-01-29: Vertex Pharmaceuticals Incorporated Sees FY2014 Sales \$570.0M-600.0M vs \$621.0M Est

Financial news for VRTX dated on 2014-01-29: Vertex Pharmaceuticals Incorporated Reports Q4 EPS of \$0.19; Revenue of \$351.20M

Financial news for VRTX dated on 2014-01-15: Vertex CEO Says Considering Sale of Hepatitis C Drug -Scrip Intelligence

Financial news for VRTX dated on 2014-01-13: UPDATE: Vertex Sees FY14 Adj. Oper.

Costs \$900-950M, Sees Kalydeco Sales \$470-500M

Financial news for VRTX dated on 2014-01-13: Form 8-K from Vertex Pharma Shows Co. Expecting FY14 Net Sales \$570-600M vs \$660M Est.

Financial news for VRTX dated on 2014-01-12: Vertex Sees 2014 Net Revenues \$570M-\$600M

Financial news for VRTX dated on 2014-01-09: Vertex Reports Sustained Viral Response 83% in Treatment-Naive Genotype 1 on Combo with Daclatasvir for HCV

Financial news for VRTX dated on 2014-01-06: UBS Upgrades Vertex Pharmaceuticals Incorporated to Buy

Financial news for VRTX dated on 2013-12-19: Benzinga's Top #PreMarket Losers

Financial news for VRTX dated on 2013-12-19: Vertex Pharma Says Phase 3 Study Results of Ivacaftor Did Not Meet Primary Endpoint

Financial news for VRTX dated on 2013-12-17: EMA Says Will Discuss Extension of Indication for Merck's Noxafil, Isentress, Pfizer's Vfend, Amgen's Xgeva, Vertex Pharma's Kalydeco

Financial news for VRTX dated on 2013-12-11: Trade Idea of the Day: Short Vertex

Financial news for VRTX dated on 2013-11-22: Form 8-K from Vertex Pharma Shows J&J's Janssen Will Make \$152M Payment Related to Incivo Sales Royalties During Q4

Financial news for VRTX dated on 2013-11-20: US Stock Futures Edge Lower Ahead Of FOMC Minutes, Economic Data

Financial news for VRTX dated on 2013-11-20: Vertex Sells INCIVO Product Royalty Rights to Janssen Pharmaceutica for \$152M

Financial news for VRTX dated on 2013-11-12: Gilead Sciences Leads In Rising Short Interest Among Biotechs

Financial news for VRTX dated on 2013-10-30: Summer Street Downgrades Vertex Pharmaceuticals Incorporated to Neutral

Financial news for VRTX dated on 2013-10-29: BofA Raises Price Target on Vertex from \$103 to \$111

Financial news for VRTX dated on 2013-10-29: Vertex Pharma Reports Q3 Adj. Loss of \$0.32/Share vs Loss of \$0.35/Share Est.; Says Will Cut 370 Jobs, Expecting \$35-45M Charge

Financial news for VRTX dated on 2013-10-25: Short Sellers Retreat From Biogen Idec, Move On Pharmacyclics (BIIB, BMRN, PCYC)

Financial news for VRTX dated on 2013-10-18: Vertex Announces Oral Selective JAK3 Inhibitor VX-509 Shows Statistically Significant Improvement in RA Phase 2b Study

Financial news for VRTX dated on 2013-10-11: Short Sellers Move On Amgen, Vertex (AMGN, PCYC, VRTX)

Financial news for VRTX dated on 2013-09-30: Vertex Issues sNDA for KALYDECO

Financial news for VRTX dated on 2013-09-25: BioMarin, Celgene Lead Trend in Biotech Short Interest (BRMN, CELG, REGN)

Financial news for VRTX dated on 2013-09-14: Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, CELG, PCYC)

Financial news for VRTX dated on 2013-09-11: Vertex, Ametek to Join S&P 500, AMD, SAIC to Join MidCap 400, Capstead to Join SmallCap 600

Financial news for VRTX dated on 2013-08-27: Short Interest In Celgene, Onyx Continues To Shrink (CELG, ONXX, VRTX)

Financial news for VRTX dated on 2013-08-21: Oppenheimer Initiates Coverage on Vertex Pharmaceuticals Incorporated at Outperform, Announces \$105.00 PT

Financial news for VRTX dated on 2013-08-21: Oppenheimer Initiates Coverage on Vertex Pharmaceuticals Incorporated at Outperform, Announces \$105.00 PT

Financial news for VRTX dated on 2013-07-29: UPDATE: Vertex Updates Recent Progress and Upcoming Milestones in Clinical Development Programs

Financial news for VRTX dated on 2013-07-29: Vertex Pharmaceuticals Incorporated Reports Q2 EPS of \$(0.03) Which May Not Compare \$(0.18) Est; Revenue of \$311.0M Which May Not Compare \$308.02M Est

Financial news for VRTX dated on 2013-07-26: Market Wrap for Friday, July 26: Stocks Grind Out Small Gains to Close Week

Financial news for VRTX dated on 2013-07-26: Weekly Preview: Earnings Season Continues, Fed In Focus, Economic Maelstrom Expected

Financial news for VRTX dated on 2013-07-26: Short Interest in Pharmacyclics Plunges (AMGN, ONXX, PCYC)

Financial news for VRTX dated on 2013-07-26: UBS Downgrades Vertex Pharmaceuticals to Neutral

Financial news for VRTX dated on 2013-07-26: Benzinga Market Primer: Friday, July 26: Futures Flat On Mixed Global Stocks Overnight

Financial news for VRTX dated on 2013-07-25: Vertex Provides Update on Ongoing All-Oral Studies of VX-135 in Hepatitis C

Financial news for VRTX dated on 2013-07-17: Kris Jenner of Rock Springs Capital Mentioning Vertex, Gilead, Pharmacyclics

Financial news for VRTX dated on 2013-07-11: Short Interest Rises in Gilead Sciences, Onyx Pharmaceuticals (BIIB, GILD, ONXX)

Financial news for VRTX dated on 2013-06-26: Short Interest in Biogen Idec and Vertex Shrinks (BIIB, CELG, VRTX)

Financial news for VRTX dated on 2013-06-18: Jefferies Says Analysis on Elan Supports \$19/Share Takeover Bid, Lifts Price Target to \$19

Financial news for VRTX dated on 2013-06-12: Short Interest Falls in Vertex, Rises in Biogen Idec (VRTX, BIIB)

Financial news for VRTX dated on 2013-06-11: Vertex Shares Move Higher, May be Attributed to Positive Street.com Article

Financial news for VRTX dated on 2013-06-07: Mid-Afternoon Market Update: Markets Cool Off Slightly, Vertex Rises

Financial news for VRTX dated on 2013-06-07: Vertex Says Company has Issued No News to Account for Strength in Stock Price Today

Financial news for VRTX dated on 2013-05-30: Alios BioPharma Initiates Phase 1 Clinical Trial for Respiratory Syncytial Virus (RSV) Infection

Financial news for VRTX dated on 2013-05-29: Short Interest in Vertex Rises, in Biogen Idec Falls

Financial news for VRTX dated on 2013-05-17: Wunderlich Initiates Coverage on Vertex Pharmaceuticals Incorporated at Buy, Announces \$4.00 PT

Financial news for VRTX dated on 2013-05-11: Short Interest in Vertex Rises, in Celgene Falls

Financial news for VRTX dated on 2013-05-10: S&P Highlights Biotech ETFs

Financial news for VRTX dated on 2013-05-01: UBS Maintains Buy on Vertex Pharmaceuticals Incorporated, Raises PT to \$86.00

Financial news for VRTX dated on 2013-05-01: Benzinga Market Primer: Wednesday, May 1

Financial news for VRTX dated on 2013-04-30: Vertex Pharmaceuticals Incorporated Reports Q1 EPS of \$0.03 vs \$(0.19) Est; Revenue of \$328.40M vs \$308.02M Est

Financial news for VRTX dated on 2013-04-30: Benzinga Market Primer: Tuesday, April 30

Financial news for VRTX dated on 2013-04-26: Weekly Preview: Focus Shifts from Earnings to Economy

Financial news for VRTX dated on 2013-04-26: Short Sellers Move into Celgene, Regeneron

Financial news for VRTX dated on 2013-04-26: Edison Investment Research Comments on Vertex Pharmaceuticals' VX-661 Data

Financial news for VRTX dated on 2013-04-25: Benzinga's M&A Chatter for Thursday April 25, 2013

Financial news for VRTX dated on 2013-04-25: Hearing Unconfirmed Chatter of Vertex Interest in Sarepta

Financial news for VRTX dated on 2013-04-24: Vertex Says New Data Showed High Viral Cure Rates with a Total of 12 and 24 Weeks of Telaprevir Combination Treatment

Financial news for VRTX dated on 2013-04-23: ALS-2200 (VX-135) Viral Kinetic Study Shows Significant Reduction in HCV RNA in People with Genotype 1 Hepatitis C Virus Infection and Cirrhosis, and in People with Genotypes 2, 3 or 4 HCV Infection

Financial news for VRTX dated on 2013-04-22: Morgan Stanley Maintains Equal-weight on Vertex Pharmaceuticals Incorporated, Raises PT to \$91.00

Financial news for VRTX dated on 2013-04-19: Market Wrap for Friday, April 19: S&P 500 and Nasdaq Composite Jump; Dow Lags After IBM Earnings

Financial news for VRTX dated on 2013-04-19: Mid-Afternoon Market Update: The Dow Turns Green; Chipotle Continues to Rise

Financial news for VRTX dated on 2013-04-19: Mid-Day Market Update: Celanese Jumps On Upbeat Results, Rambus Declines

Financial news for VRTX dated on 2013-04-19: UPDATE: Deutsche Bank Raises PT on Vertex Pharmaceuticals on 661 Data

Financial news for VRTX dated on 2013-04-19: Vertex News Lifts Biotech ETFs

Financial news for VRTX dated on 2013-04-19: Stocks Hitting 52-Week Highs

Financial news for VRTX dated on 2013-04-19: Mid-Morning Market Update: Markets Mixed, General Electric Q1 Profit Surges 16%

Financial news for VRTX dated on 2013-04-19: UPDATE: Credit Suisse Raises PT on Vertex Pharmaceuticals on Cystic Fibrosis Franchise De-Risking

Financial news for VRTX dated on 2013-04-19: Option Alert: Vertex April 60 Call Rises 45,000%

Financial news for VRTX dated on 2013-04-19: UPDATE: Goldman Sachs Upgrades Vertex Pharmaceuticals to Neutral on '661/Kalydeco Data

Financial news for VRTX dated on 2013-04-19: UPDATE: Canaccord Upgrades Vertex Pharmaceuticals to Buy Following Release of VX-661 Data

Financial news for VRTX dated on 2013-04-19: Benzinga's Top Upgrades

Financial news for VRTX dated on 2013-04-19: Citigroup Maintains Buy on Vertex Pharmaceuticals Incorporated, Raises PT to \$100.00

Financial news for VRTX dated on 2013-04-19: Goldman Sachs Upgrades Vertex Pharmaceuticals Incorporated to Neutral, Raises PT to \$86.00

Financial news for VRTX dated on 2013-04-19: Canaccord Genuity Upgrades Vertex Pharmaceuticals Incorporated to Buy, Raises PT to \$96.00

Financial news for VRTX dated on 2013-04-18: Vertex Rises \$30 After-Hours on Positive Cystic Fibrosis Data

Financial news for VRTX dated on 2013-04-18: Treatment with VX-661 and Ivacaftor in a Phase 2 Study Resulted in Statistically Significant Improvements in Lung Function in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation

Financial news for VRTX dated on 2013-04-10: Short Sellers Move Out of Amgen, Celgene, Pharmacyclics

Financial news for VRTX dated on 2013-04-08: UPDATE: Canaccord Initiates Vertex Pharmaceuticals with Hold on VX-809/Kalydeco Combination Therapy

Financial news for VRTX dated on 2013-04-08: Canaccord Genuity Initiates Coverage on Vertex Pharmaceuticals Incorporated at Hold, Announces \$55.00 PT

Financial news for VRTX dated on 2013-04-05: Vertex, Bristol-Myers Enter Deal for Phase 2 All-Oral Studies of VX-135

Financial news for VRTX dated on 2013-03-28: Short Sellers Dump Amgen, Focus on

Celgene, Gilead Sciences

Financial news for VRTX dated on 2013-03-25: Moving Averages Indicate These Sector ETFs Could be Stretched

Financial news for VRTX dated on 2013-03-25: Stocks to Watch Next Week

Financial news for VRTX dated on 2013-03-22: Friday March 22th Watchlist

Financial news for VRTX dated on 2013-03-19: UPDATE: JP Morgan Raises PT on Vertex Pharmaceuticals on Phase 3 Trials

Financial news for VRTX dated on 2013-03-19: JP Morgan Maintains Overweight on Vertex Pharmaceuticals Incorporated, Raises PT to \$86.00

Financial news for VRTX dated on 2013-03-12: Short Interest Swings in Biotech Stocks (AMGN, CELG, PCYC)

Financial news for VRTX dated on 2013-03-05: Summer Street Says Fast Track Unlikely for Sarepta's Eteplirsen

Financial news for VRTX dated on 2013-03-04: Vertex Announces VX-787 Showed Significant Antiviral Activity, Reduced Severity, Duration of Flu Systems in Phase 2 Study, Met Primary Endpoint

Financial news for VRTX dated on 2013-03-01: Vertex Pharma Files Automatic Mixed Securities Shelf

Financial news for VRTX dated on 2013-02-28: Short Interest Swings in Biotech Stocks (ALXN, AMGN, CELG)

Financial news for VRTX dated on 2013-02-26: Vertex Pharma Announces Initiation of Pivotal Phase 3 Program of VX-809

Financial news for VRTX dated on 2013-02-12: Short Interest Swings in Biotech Stocks (AMGN, CELG, ONXX)

Financial news for VRTX dated on 2013-02-01: Ireland Approves Funding for KALYDECO for Treatment of G551D

Financial news for VRTX dated on 2013-02-01: Kalydeco Approved in Ireland for Cystic Fibrosis Patients

Financial news for VRTX dated on 2013-01-29: Vertex Pharmaceuticals Incorporated Sees FY2013 Sales \$1.10B-1.25B vs \$1.13B Est

Financial news for VRTX dated on 2013-01-29: Vertex Pharmaceuticals Reports Q4 Non-GAAP EPS of \$0.04 Excluding Items, Revenue of \$334 Million vs \$318.1 Million Est.

Financial news for VRTX dated on 2013-01-26: Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)

Financial news for VRTX dated on 2013-01-15: Vertex Pharma Shares Sink on Lazard Downgrade

Financial news for VRTX dated on 2013-01-09: Vertex Pharma CEO Says Co. to Focus on Developing Specialty Diseases, Seeking a Partner for Rheumatoid Arthritis Compound

Financial news for VRTX dated on 2013-01-02: Janney Capital Initiates Coverage on Vertex Pharmaceuticals Incorporated at Buy, Announces \$54.00 PT

Financial news for VRTX dated on 2012-12-28: Short Interest Swings in Biotech Stocks (CELG, GILD, REGN)

Financial news for VRTX dated on 2012-12-19: Vertex Pharma Reports Update to US Prescribing Info for INCIVEK

Financial news for VRTX dated on 2012-12-12: Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)

Financial news for VRTX dated on 2012-12-07: UPDATE: Deutsche Bank Reiterates Buy Rating, Lowers PT on Vertex Pharmaceuticals

Financial news for VRTX dated on 2012-12-07: Deutsche Bank Maintains Buy on Vertex Pharmaceuticals Incorporated, Lowers PT to \$75.00

Financial news for VRTX dated on 2012-12-03: Vertex Says Health Canada Approves KALYDECO

Financial news for VRTX dated on 2012-12-02: BioMarin, Prestige Brands and Other Top Performing Health Care Stocks in November

Financial news for VRTX dated on 2012-12-01: RIM, Green Mountain and Other Top Performing Nasdaq Stocks in November

Financial news for VRTX dated on 2012-11-28: Benzinga's M&A Chatter for Wednesday November 28, 2012

Financial news for VRTX dated on 2012-11-28: UPDATE: Hearing Chatter Vertex May Buy North American Rights from Sarepta -Adam F Tweet

Financial news for VRTX dated on 2012-11-28: Hearing Unconfirmed Takeover Chatter in Sarepta

Financial news for VRTX dated on 2012-11-28: Argus Research Downgrades Vertex Pharmaceuticals from Buy to Hold

Financial news for VRTX dated on 2012-11-12: Short Interest Swings in Biotech Stocks (AMGN, BIIB, VRTX)

Financial news for VRTX dated on 2012-11-12: UPDATE: Credit Suisse Downgrades Vertex Pharmaceuticals to Neutral on Competitive Pressures

Financial news for VRTX dated on 2012-11-12: Credit Suisse Downgrades Vertex Pharmaceuticals from Outperform to Neutral, Lowers PT from \$56 to \$48

Financial news for VRTX dated on 2012-11-03: Moves in Smaller Health Care Stocks (GMED, SEM, UAM, VRTX)

Financial news for VRTX dated on 2012-11-02: Benzinga Mid-Morning Market Update

Financial news for VRTX dated on 2012-11-02: UPDATE: Goldman Sachs Downgrades Vertex Pharmaceuticals to Sell on CF Combo Outlook

Financial news for VRTX dated on 2012-11-02: Credit Suisse Maintains Vertex Pharmaceuticals at Outperform, Lowers PT from \$58 to \$56

Financial news for VRTX dated on 2012-11-02: Goldman Sachs Downgrades Vertex Pharmaceuticals from Neutral to Sell, Lowers PT from \$55 to \$43

Financial news for VRTX dated on 2012-11-01: UPDATE: Vertex Pharmaceuticals Reports Q3 EPS \$-0.27 vs \$0.20 Est; Revenues \$336M vs \$377.14M Est

Financial news for VRTX dated on 2012-11-01: Vertex Pharmaceuticals Reports Q3 EPS \$0.13 vs \$0.20 Est; Revenues \$336M vs \$377.14M Est

Financial news for VRTX dated on 2012-11-01: Vertex, JNJ's Janssen Enter Agreement for Phase 2 Hepatitis C Study

Financial news for VRTX dated on 2012-11-01: Vertex, GlaxoSmithKline Enter Agreement for Phase 2 Hepatitis C Study

Financial news for VRTX dated on 2012-10-29: Earnings Preview: Vertex Pharmaceuticals

Financial news for VRTX dated on 2012-10-29: Earnings Scheduled For October 29, 2012

Financial news for VRTX dated on 2012-10-25: Short Interest Swings in Biotech Stocks (BIIB, GILD, VVUS)

Financial news for VRTX dated on 2012-10-23: Adam Feuerstein Says Sarepta Takeover Target, Possibly by Vertex

Financial news for VRTX dated on 2012-10-22: Vertex Spikes to Lows

Financial news for VRTX dated on 2012-10-15: Short Interest Swings in Biotech Stocks (BIIB, CELG, GILD)

Financial news for VRTX dated on 2012-10-11: Adam Feuerstein Gets Positive Comments on Vertex VX809/Kalydeco Data

Financial news for VRTX dated on 2012-10-11: Vertex Says Did Not See Significant Difference in Weight Gain

Financial news for VRTX dated on 2012-10-11: Vertex Pharmaceuticals Spikes Lower

Financial news for VRTX dated on 2012-10-11: Vertex Pharmaceuticals Spikes Higher on Release of Positive Data

Financial news for VRTX dated on 2012-10-11: Vertex Says Data from Phase 2 VX-809 Study Supports Plan for Program in Early 2013

Financial news for VRTX dated on 2012-10-09: UPDATE: Deutsche Bank Initiates Vertex Pharmaceuticals at Buy on Cystic Fibrosis Outlook

Financial news for VRTX dated on 2012-10-09: Deutsche Bank Initiates Coverage on Vertex Pharmaceuticals at Buy, Announces PT of \$77

Financial news for VRTX dated on 2012-10-04: Argus Initiates Coverage Vertex Pharmaceuticals at Buy, Announces PT of \$68

Financial news for VRTX dated on 2012-10-01: Vertex Pharma Reports Presentation of New Data from Hepatitis C

Financial news for VRTX dated on 2012-10-01: Alios Biopharma Says Compounds Result in Potent Antiviral Activity; Sees Clinical Trial in 2013

Financial news for VRTX dated on 2012-09-25: Vertex Pharma Says AL-2158 Development Discontinued on Lack of Efficacy

Financial news for VRTX dated on 2012-09-18: Yuchun Lee Appointed to the Vertex Board of Directors

Financial news for VRTX dated on 2012-09-04: Vertex Announces Appointment of Stuart A. Arbuckle as CCO

Financial news for VRTX dated on 2012-08-27: Short Interest in Biotech Firms on the Rise

Financial news for VRTX dated on 2012-08-24: Bristol-Myers' Trash is Gilead Sciences' Treasure

Financial news for VRTX dated on 2012-08-17: Idenix Shares Plunge After Hepatitis Drug Study Put on Hold

Financial news for VRTX dated on 2012-08-14: Vertex Pharmaceuticals Spokesperson Says No News to Account for Tuesday's Move

Financial news for VRTX dated on 2012-08-14: Vertex Pharmaceuticals Spikes Higher

Financial news for VRTX dated on 2012-07-31: UBS Maintains Vertex Pharmaceuticals at Buy, Lowers PT from \$63 to \$60

Financial news for VRTX dated on 2012-07-31: UPDATE: Bank of America Lowers Price Target on Vertex Pharmaceuticals from \$71 to \$66

Financial news for VRTX dated on 2012-07-31: Citigroup Maintains Vertex Pharmaceuticals at Buy, Lowers PT from \$66 to \$63

Financial news for VRTX dated on 2012-07-31: Bank of America Maintains Vertex Pharmaceuticals at Buy, Lowers PT from \$71 to \$66

Financial news for VRTX dated on 2012-07-31: Piper Jaffray Downgrades Vertex Pharmaceuticals from Overweight to Neutral

Financial news for VRTX dated on 2012-07-31: Goldman Sachs Maintains Vertex Pharmaceuticals at Neutral, Lowers PT from \$60 to \$55

Financial news for VRTX dated on 2012-07-30: Vertex Provides Updates on Progress in Research and Development Programs in Hepatitis C and Cystic Fibrosis

Financial news for VRTX dated on 2012-07-30: Vertex Pharmaceuticals Reports Q2 EPS \$0.46 vs \$0.59 Est; Revenues \$418.3M vs \$472.16M Est

Financial news for VRTX dated on 2012-07-30: Benzinga Market Primer, Monday July 30

Financial news for VRTX dated on 2012-07-30: Possible Hepatitis C Outbreak Could Lift This ETF

Financial news for VRTX dated on 2012-07-27: European Commission Approves Vertex Drug Kalydeco Ahead of Monday Earnings -IBD

Financial news for VRTX dated on 2012-07-10: Dendreon, Pharmacyclics and Other Biotech Takeover Targets

Financial news for VRTX dated on 2012-07-05: S&P: Not All Mid-Cap ETFs Created Equal (MDY, VO)

Financial news for VRTX dated on 2012-06-28: Vertex Pharmaceuticals Falls 20% on JP Morgan Report

Financial news for VRTX dated on 2012-06-28: JP Morgan Buyer on Vertex Pharmaceuticals' Weakness

Financial news for VRTX dated on 2012-06-28: Social Media Outlook for Thursday June 28 (ENOC, ENTR, JPM, VRTX)

Financial news for VRTX dated on 2012-06-28: Financial Breakfast: Morning News Summary for June 28, 2012

Financial news for VRTX dated on 2012-06-28: Vertex Announces Final Data from Phase 2 Combination Study of VX-809 and KALYDECO(tm) (ivacaftor) Showed Statistically Significant Improvements in Lung Function in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation

Financial news for VRTX dated on 2012-06-26: Long Options to Take Profits (Without Selling Stock)

Financial news for VRTX dated on 2012-06-19: Option Alert: Vertex Pharmaceuticals July 70 Call; Block Trade: 3,600 Contracts; Currently \$58.47

Financial news for VRTX dated on 2012-06-07: Vertex Studying Drug Combination for Cystic Fibrosis -Bloomberg

Financial news for VRTX dated on 2012-06-07: Senator Charles Grassley Calls on SEC to Investigate Vertex

Financial news for VRTX dated on 2012-06-07: UPDATE: Vertex Says Kalydeco for Treatment of Cystic Fibrosis

Financial news for VRTX dated on 2012-06-07: Vertex Pharma Says Kalydeco Showed Lung Function Improvement, Improvements Durable Up to 96 Weeks

Financial news for VRTX dated on 2012-06-07: Vertex Pharmaceuticals Spiking Lower

Financial news for VRTX dated on 2012-06-05: Survive The Summer With These ETFs (PEJ, NUGT, FBT)

Financial news for VRTX dated on 2012-05-30: FDA Issues Warning Letter on Vertex Incivek

Financial news for VRTX dated on 2012-05-29: Morgan Stanley Lowers PT on Vertex Pharmaceuticals After Corrected CF Data

Financial news for VRTX dated on 2012-05-29: Vertex Pharmaceuticals Trading 12.1% Lower on Heavy Volume; Currently at \$57.03

Financial news for VRTX dated on 2012-05-29: Vertex Pharmaceuticals Down 17% After Revising Study Results

Financial news for VRTX dated on 2012-05-29: Social Media Outlook for Tuesday May 29 (BID, IBM, VRTX, MSFT)

Financial news for VRTX dated on 2012-05-29: JP Morgan Reiterates Overweight on Vertex Pharmaceuticals on Continued Share Upside Amid Weakness

Financial news for VRTX dated on 2012-05-29: Vertex Says Conclusions and Plans Haven't Changed with New Data; High Dose of CF Drug Showed Most Robust Results

Financial news for VRTX dated on 2012-05-29: Benzinga's Top Pre-Market Losers

Financial news for VRTX dated on 2012-05-29: Vertex Pharmaceuticals Falls 25% Pre-Market on Revised Phase 2 Data

Financial news for VRTX dated on 2012-05-29: Vertex Pharmaceuticals Falls 15% Pre-Market on Corrected Phase 2 Data

Financial news for VRTX dated on 2012-05-29: Vertex Pharmaceuticals Resumes Trading

Financial news for VRTX dated on 2012-05-29: PREVIEW: Vertex Pharmaceuticals to Resume Trading at 7:20am

Financial news for VRTX dated on 2012-05-29: Vertex Pharmaceuticals Halted; Pending News

Financial news for VRTX dated on 2012-05-29: Vertex Corrects and Provides Additional Data from Recent Interim Analysis of Phase 2 Combination Study of VX-809 and

KALYDECO(tm) (ivacaftor) in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation

Financial news for VRTX dated on 2012-05-25: Vertex Receives European CHMP Positive Opinion for KALYDECO(tm) (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis

Financial news for VRTX dated on 2012-05-24: Vertex Appoints David Altshuler to its Board of Directors

Financial news for VRTX dated on 2012-05-21: The Definitive Biotech ETF Guide (IBB, XBI, FBT)

Financial news for VRTX dated on 2012-05-15: S&P Bullish On Biotech ETFs (FBT, IBB, XBI)

Financial news for VRTX dated on 2012-05-14: Benzinga's Top Upgrades with Color for May 14, 2012

Financial news for VRTX dated on 2012-05-14: UPDATE: J.P. Morgan Upgrades Vertex Pharmaceuticals; Raises PT

Financial news for VRTX dated on 2012-05-14: JP Morgan Upgrades Vertex Pharmaceuticals from Neutral to Overweight, Raises PT from \$45 to \$82

Financial news for VRTX dated on 2012-05-11: UPDATE: Goldman Sachs Maintains Neutral Rating, Raises PT for Vertex Pharmaceuticals

Financial news for VRTX dated on 2012-05-11: Goldman Sachs Maintains Vertex Pharmaceuticals at Neutral, Raises PT from \$40 to \$60

Financial news for VRTX dated on 2012-05-08: Benzinga's Top Upgrades with Color for May 8, 2012

Financial news for VRTX dated on 2012-05-08: Social Media Outlook for Tuesday May 8 (LPX, DTV, MAKO, FOSL)

Financial news for VRTX dated on 2012-05-08: UPDATE: Brean Murray Carret & Co. Upgrades Vertex Pharmaceuticals

Financial news for VRTX dated on 2012-05-08: Financial Breakfast: Morning News Summary for May 8, 2012

Financial news for VRTX dated on 2012-05-08: UPDATE: Morgan Stanley Upgrades Vertex Pharmaceuticals to Equal-Weight; Interim CF Data

Financial news for VRTX dated on 2012-05-08: Morgan Stanley Upgrades Vertex Pharmaceuticals from Underweight to Equal-weight, Raises PT from \$28 to \$51

Financial news for VRTX dated on 2012-05-08: Brean Murray Carret & Co. Upgrades Vertex Pharmaceuticals from Hold to Buy, Announces PT of \$69

Financial news for VRTX dated on 2012-05-07: Vertex Pharmaceuticals Trading 52.8% Higher on Heavy Volume; Currently at \$57.16

Financial news for VRTX dated on 2012-05-07: Vertex Pharmaceuticals Soars on Promising Drug Data

Financial news for VRTX dated on 2012-05-07: Vertex Pharma Stock Jumps on Cystic Fibrosis Data - IBD

Financial news for VRTX dated on 2012-05-07: Piper Jaffray Raises Vertex Pharmaceuticals Price Target from \$56 to \$75

Financial news for VRTX dated on 2012-05-07: J.P. Morgan Reiterates Neutral Rating for Vertex Pharmaceuticals

Financial news for VRTX dated on 2012-05-07: Social Media Outlook for Monday May 7 (VRTX, TSN, AIG, MSFT)

Financial news for VRTX dated on 2012-05-07: Benzinga's Top Upgrades with Color for May 7, 2012

Financial news for VRTX dated on 2012-05-07: UPDATE: ISI Group Upgrades Vertex Pharmaceuticals

Financial news for VRTX dated on 2012-05-07: Vertex Pharmaceuticals Pops 60% on Positive Phase 2 Study

Financial news for VRTX dated on 2012-05-07: ISI Group Upgrades Vertex Pharmaceuticals from Neutral to Buy, Announces PT of \$68

Financial news for VRTX dated on 2012-05-07: Vertex Pharmaceuticals Resumes Trading

Financial news for VRTX dated on 2012-05-07: Vertex Announces Interim Data from Phase 2 Combination Study of VX-809 and KALYDECO Showed Significant Improvements in Lung Function in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation

Financial news for VRTX dated on 2012-05-07: Vertex Pharmaceuticals Halted for Pending News

Financial news for VRTX dated on 2012-04-26: Vertex Pharmaceuticals Reports Q1 EPS \$0.55 vs \$0.57 Est; Revenues \$438.7M vs \$452.29M Est

Financial news for VRTX dated on 2012-04-18: Vertex Advances INCIVEK and Broad Portfolio of Medicines in Development With Goal of Further Expanding and Improving Treatment for People With Hepatitis C

Financial news for VRTX dated on 2012-04-17: Option Alert: Vertex Pharmaceuticals May 38 Call; Block Trade, 2,250 Contracts

Financial news for VRTX dated on 2012-04-13: UBS Maintains Vertex Pharmaceuticals at Neutral, Lowers PT from \$44 to \$41

Financial news for VRTX dated on 2012-03-28: UBS Maintains Vertex Pharmaceuticals at Neutral, Raises PT from \$35 to \$44

Financial news for VRTX dated on 2012-03-19: Benzinga's Top Downgrades

Financial news for VRTX dated on 2012-03-19: Financial Breakfast: Morning News Summary for March 19, 2012

Financial news for VRTX dated on 2012-03-19: UPDATE: Morgan Stanley Downgrades Vertex Pharmaceuticals to Underweight

Financial news for VRTX dated on 2012-03-19: Morgan Stanley Downgrades Vertex Pharmaceuticals from Equal-weight to Underweight, Maintains PT at \$30

Financial news for VRTX dated on 2012-03-14: Bank of America Maintains Vertex Pharmaceuticals at Buy, Raises PO from \$41 to \$49

Financial news for VRTX dated on 2012-03-09: Hearing Summer Street Positive on Vertex Pharmaceuticals, PT \$57

Financial news for VRTX dated on 2012-03-06: Data from Phase 2 Study of an INCIVEK(r) Combination Regimen Showed 74% of People Co-Infected with Hepatitis C and HIV Had Undetectable Hepatitis C Virus 12 Weeks After Treatment Ended (SVR12)

Financial news for VRTX dated on 2012-02-29: Vertex Pharmaceuticals Trading 1.5% Higher on Heavy Volume; Currently at \$38.84

Financial news for VRTX dated on 2012-02-27: Benzinga's M&A Chatter for Monday February 27, 2012

Financial news for VRTX dated on 2012-02-27: Positive Rumors Circulate About Vertex Pharmaceuticals

Financial news for VRTX dated on 2012-02-23: Vertex Announces 12-Week On-Treatment Data and SVR4 From Phase 2 Study of Interferon-Free (All-Oral) Treatment Regimen of INCIVEK(r), VX-222 and Ribavirin in People with Genotype 1 Hepatitis C

Financial news for VRTX dated on 2012-02-21: Top 4 NASDAQ Stocks In The Biotechnology Industry With The Lowest PEG Ratio

Financial news for VRTX dated on 2012-02-17: Gilead Falls On Disappointing Hep C Drug Data; Analysts Remain Bullish

Financial news for VRTX dated on 2012-02-17: Gilead Sciences Negative Data Ripples through Biotech Field, Boosting Vertex, Achillion; Knocking Idenix

Financial news for VRTX dated on 2012-02-17: Vertex Pharmaceuticals Seeing Strength this Morning after Gilead's Negative Results

Financial news for VRTX dated on 2012-02-17: Vertex Pharmaceuticals Rises 9% Pre-Market, \$41.01

Financial news for VRTX dated on 2012-02-14: Benzinga's M&A Chatter for Tuesday February 14, 2012

Financial news for VRTX dated on 2012-02-14: Hearing Renewed Takeover Chatter in Vertex Pharmaceuticals

Financial news for VRTX dated on 2012-02-08: Benzinga's M&A Chatter for Wednesday February 8, 2012

Financial news for VRTX dated on 2012-02-08: Positive Rumors Circulate About Vertex Pharmaceuticals

Financial news for VRTX dated on 2012-02-08: Hearing Takeover Chatter in Vertex

Financial news for VRTX dated on 2012-02-03: Vertex Pharma Down 5% After INCIVEK sales disappoint.

Financial news for VRTX dated on 2012-02-03: UPDATE: Goldman Sachs Downgrades Vertex Pharmaceuticals to Neutral

Financial news for VRTX dated on 2012-02-03: Benzinga's Top Downgrades

Financial news for VRTX dated on 2012-02-03: Goldman Sachs Downgrades Vertex Pharma to Neutral

Financial news for VRTX dated on 2012-02-02: Benzinga's M&A Chatter for Thursday February 2, 2012

Financial news for VRTX dated on 2012-02-02: Vertex Pharmaceuticals Reports Q4 EPS \$0.86 vs \$0.70 Est; Revenues \$563.30M vs \$518.36M Est

Financial news for VRTX dated on 2012-02-02: Achillion Pharmaceuticals Spokesperson Would Not Comment on Rumor of Vertex Offer

Financial news for VRTX dated on 2012-02-02: Hearing Achillion Pharmaceuticals Accepted \$19.75 Offer From Vertex, Not Confirmed

Financial news for VRTX dated on 2012-02-02: Positive Rumors Circulate About Achillion Pharmaceuticals

Financial news for VRTX dated on 2012-01-31: Vertex Pharmaceutical Resumes Trading

Financial news for VRTX dated on 2012-01-31: PREVIEW: Vertex Pharma to Resume Trading 1:35 p.m.

Financial news for VRTX dated on 2012-01-31: Vertex Pharma Surging on FDA Approval

Financial news for VRTX dated on 2012-01-31: Vertex Pharmaceutical Says Could See European Approval for Kalydeco in Q3 -Reuters

Financial news for VRTX dated on 2012-01-31: Vertex Pharmaceuticals Halted for News Pending

Financial news for VRTX dated on 2012-01-31: UPDATE: Vertex Pharmaceuticals Confirms FDA Approves KALYDECO, the First Medicine to Treat the Underlying Cause of Cystic Fibrosis

Financial news for VRTX dated on 2012-01-31: Vertex Pharmaceuticals Trading 9.7% Higher on Heavy Volume; Currently at \$38.11

Financial news for VRTX dated on 2012-01-31: Vertex Pharmaceuticals Trading 7.8% Higher on FDA Approval

Financial news for VRTX dated on 2012-01-31: FDA Approves Vertex's Kalydeco for Cystic Fibrosis

Financial news for VRTX dated on 2012-01-31: Vertex Pharmaceuticals Trading 3.8% Higher on Heavy Volume; Currently at \$36.05

Financial news for VRTX dated on 2012-01-24: Benzinga's M&A Chatter for Tuesday January 24, 2012

Financial news for VRTX dated on 2012-01-24: Achillion Pharmaceuticals Spiking Higher on Renewed Takeover Chatter

Financial news for VRTX dated on 2012-01-18: Benzinga's M&A Chatter for Wednesday January 18, 2012

Financial news for VRTX dated on 2012-01-18: Positive Rumors Circulate About Vertex Pharmaceuticals

Financial news for VRTX dated on 2012-01-18: Hearing Takeover Chatter in Vertex

Financial news for VRTX dated on 2012-01-10: Going Nuc-lear on Hepatitis C -- Is Idenix the Next Target?

Financial news for VRTX dated on 2012-01-09: A Peek Into The Market Before The Trading Starts

Financial news for VRTX dated on 2012-01-09: Vertex Announces Key 2012 Business Objectives as Company Prepares for Planned Global Launch of KALYDECO in Cystic Fibrosis

Financial news for VRTX dated on 2012-01-08: Vertex Announces Key 2012 Business Objectives as Company Prepares for Planned Global Launch of KALYDECO in Cystic Fibrosis

Financial news for VRTX dated on 2012-01-03: Piper Jaffray Reiterates Overweight, \$56 PT On Vertex

Financial news for VRTX dated on 2011-12-27: Best Biotech Stocks of 2011

Financial news for VRTX dated on 2011-12-19: RBC Capital Upgrades Vertex Pharmaceuticals to Top Pick

Financial news for VRTX dated on 2011-12-15: Benzinga's M&A Chatter for Thursday December 15, 2011

Financial news for VRTX dated on 2011-12-15: FDA Grants Priority Review for KALYDECO

Financial news for VRTX dated on 2011-12-15: Vertex Announces CEO Succession Plan; Jeffrey Leiden to become CEO in February 2012

Financial news for VRTX dated on 2011-12-09: Vertex and Alios BioPharma Begin Clinical Studies of Nucleotide Drug Candidates ALS-2200 and ALS-2158 for the Treatment of Hepatitis C

Financial news for VRTX dated on 2011-12-05: Citi Reiterates Buy, \$42 PT On Vertex

Financial news for VRTX dated on 2011-12-05: Piper Jaffray Maintains Overweight, \$56 Target on Vertex Pharmaceuticals

Financial news for VRTX dated on 2011-12-01: Mad Money Lightning Round: Cramer Dislikes Microsoft, Radioshack

Financial news for VRTX dated on 2011-11-28: Investor Ideas' Biotech and Pharma Stock Investor Alert for Aethlon Medical, Vertex, Pharmasset

Financial news for VRTX dated on 2011-11-28: Citi Maintains Buy Rating and \$59 PT on Vertex Pharmaceuticals

Financial news for VRTX dated on 2011-11-25: Investor Ideas' Hepatitis C Virus (HCV) Biotech and Pharma Stock Investor Alert

Financial news for VRTX dated on 2011-11-25: Vertex Pharmaceuticals Hits 52-Week Low of \$26.74

Financial news for VRTX dated on 2011-11-23: Vertex Pharmaceuticals Hits 52-Week Low of \$27.33

Financial news for VRTX dated on 2011-11-22: Vertex Pharmaceuticals Hits 52-Week Low of \$27.36

Financial news for VRTX dated on 2011-11-21: Hep-C Stocks Soar On M&A News

Financial news for VRTX dated on 2011-11-21: GILD Acquires VRUS

Financial news for VRTX dated on 2011-11-21: Vertex Pharmaceuticals Hits 52-Week Low of \$27.49

Financial news for VRTX dated on 2011-11-18: Vertex Pharmaceuticals hits 52-Week low

Financial news for VRTX dated on 2011-11-17: VRTX hits 52-Week low

Financial news for VRTX dated on 2011-11-16: VRTX hits 52-Week low

Financial news for VRTX dated on 2011-11-10: Bank of America Maintains PO on Vertex Pharmaceuticals Ahead of Fork in the Road

Financial news for VRTX dated on 2011-11-10: Morgan Stanley Upgrading Vertex

Pharmaceuticals

Financial news for VRTX dated on 2011-11-10: Financial Breakfast: Morning News Summary for November 10, 2011

Financial news for VRTX dated on 2011-11-10: Morgan Stanley Upgrades Vertex Pharmaceuticals to Equal-weight, \$32 PT

Financial news for VRTX dated on 2011-11-08: Vertex Pharmaceuticals Hits New 52-Week Low, \$31.47

Financial news for VRTX dated on 2011-11-08: UPDATE: Piper Jaffray Lowers Price Target on Vertex to \$56

Financial news for VRTX dated on 2011-11-08: Piper Jaffray Lowers PT on Vertex Pharmaceuticals to \$56

Financial news for VRTX dated on 2011-11-08: Benzinga's Top Downgrades

Financial news for VRTX dated on 2011-11-07: Afternoon Movers; DreamWorks Moves Up on Positive "Puss in Boots" Sales

Financial news for VRTX dated on 2011-11-07: Benzinga's Top Pre-Market Losers

Financial news for VRTX dated on 2011-11-05: Vertex Pharmaceuticals Announces Positive Interim Data From a Phase 2 Study of INCIVEK

Financial news for VRTX dated on 2011-11-04: Vertex Announces Recipients of Special Grants Initiative to Support People with Hepatitis C

Financial news for VRTX dated on 2011-11-03: Vertex Pharmaceuticals Announces Phase 3 Study of KALYDECO in Children Ages 6 to 11 with a Specific Type of Cystic Fibrosis Showed Significant Improvements in Lung Function and Other Measures of Disease Sustained Through 48 Weeks

Financial news for VRTX dated on 2011-10-27: Vertex Pharmaceuticals Incorporated's Earnings Report

Financial news for VRTX dated on 2011-10-27: Vertex Pharmaceuticals Reports Q3 Revenues \$659.2M May Not Compare vs \$343.42M Est

Financial news for VRTX dated on 2011-10-27: Vertex Provides Updates on INCIVEKTM Launch and Medicines in Development

Financial news for VRTX dated on 2011-10-25: Earnings Preview: Vertex Pharmaceuticals' EPS, Revenue Expected to Rise

Financial news for VRTX dated on 2011-10-24: Vertex Starts Global Phase 3b Study to Evaluate the Potential for People with Hepatitis C to Achieve a Viral Cure with a Total Treatment Duration of 12 Weeks of INCIVEK Combination Therapy

Financial news for VRTX dated on 2011-10-24: Vertex Announces Presentation of New Data for Oral JAK3 Inhibitor VX-509 at Annual Meeting of the American College of Rheumatology

Financial news for VRTX dated on 2011-10-24: Vertex Starts Global Phase 3b Study to Evaluate the Potential for People with Hepatitis C

Financial news for VRTX dated on 2011-10-19: Vertex Submits Application for Priority Review and Approval of KALYDECO in the U.S. as First Potential Medicine to Target the Underlying Cause of Cystic Fibrosis

Financial news for VRTX dated on 2011-10-13: Benzinga's Volume Movers

Financial news for VRTX dated on 2011-10-12: Piper Jaffray Maintains Overweight Rating and \$63 PT on Vertex Pharmaceuticals

Financial news for VRTX dated on 2011-10-11: Vertex Pharma Spiking Lower on Heavy Volume

Financial news for VRTX dated on 2011-10-11: Bank of America Lowers PO on Vertex Pharmaceuticals to \$55

Financial news for VRTX dated on 2011-10-11: Vertex Pharmaceuticals' INCIVEK Now Available in Canada for People with Hepatitis C

Financial news for VRTX dated on 2011-10-10: Some Stocks Are Just Too Weak To Participate

Financial news for VRTX dated on 2011-10-10: Midday Losers; Vertex Pharmaceuticals Down 9%

Financial news for VRTX dated on 2011-10-04: Keep These Stocks On The Radar

Financial news for VRTX dated on 2011-10-03: Citi Maintains Buy on Vertex Pharmaceuticals

Financial news for VRTX dated on 2011-09-27: Hearing Citigroup Making Cautious Comments on Vertex Pharma

Financial news for VRTX dated on 2011-09-06: Citi Has Buy On Vertex Pharmaceuticals

Financial news for VRTX dated on 2011-09-06: A Peek Into The Market Before The Trading Starts

Financial news for VRTX dated on 2011-09-06: Vertex Pharmaceuticals Announces Phase 2a Study of Selective Oral JAK3 Inhibitor VX-509 Showed Significant Improvements in Signs and Symptoms of Rheumatoid Arthritis

Financial news for VRTX dated on 2011-08-22: Health Canada Approves INCIVEK(TM) (telaprevir) for People With Hepatitis C

Financial news for VRTX dated on 2011-08-08: UPDATE: Citadel Securities Initiates Coverage on Vertex

Financial news for VRTX dated on 2011-08-08: Citadel Initiates Vertex Pharmaceuticals At Neutral, \$46 PT

Financial news for VRTX dated on 2011-07-28: Vertex Pharmaceuticals Narrows Loss

Financial news for VRTX dated on 2011-07-28: Vertex Pharma Reports Q2 Revenues \$114.4M

Financial news for VRTX dated on 2011-07-26: Interim Data from Phase 2 Study of Combination Regimen Including VX-222

Financial news for VRTX dated on 2011-07-26: Vertex Reports First data from Phase 2 Study of Combination Regimen Showing Potential for Viral Cure in Many Patients with a 12-week Combination Regimen of Multiple Direct-Acting Antivirals

Financial news for VRTX dated on 2011-07-25: Vertex Pharmaceuticals Earnings Preview: Analysts Expect Falling Revenue, Rising EPS Over Last Quarter

Financial news for VRTX dated on 2011-07-13: Goldman Sachs Provides Color on Biotechnology

Financial news for VRTX dated on 2011-07-12: Piper Jaffray Reiterates Overweight and PT of \$63 on Vertex Pharmaceuticals

Financial news for VRTX dated on 2011-06-23: Street Overestimating Sales of Vertex's Incivek, Morgan Stanley Reports

Financial news for VRTX dated on 2011-06-23: Morgan Stanley Lowers PT On Vertex Pharmaceuticals To \$32

Financial news for VRTX dated on 2011-06-22: Vertex Pharmaceuticals Announces New England Journal of Medicine Publishes Data From Two Phase 3 Studies of INCIVEK in Hepatitis C

Financial news for VRTX dated on 2011-06-14: J.P. Morgan Comments On Vertex Collaboration

Financial news for VRTX dated on 2011-06-13: Piper Jaffray Maintains Overweight on Vertex Pharmaceuticals

Financial news for VRTX dated on 2011-06-10: Vertex Pharmaceuticals Announces Phase 3 STRIVE Study of VX-770 Showed Durable Improvements in Lung Function and Other Measures of Disease Among People With a Specific Type of Cystic Fibrosis

Financial news for VRTX dated on 2011-06-10: Goldman Sachs Closes Out Two Losing Trades

Financial news for VRTX dated on 2011-06-10: J.P. Morgan Gives Update On VRTX

Financial news for VRTX dated on 2011-06-09: Top Percentage Gainers and Losers as of 2pm 06/09/11

Financial news for VRTX dated on 2011-06-09: Top Percentage Gainers and Losers as of

12pm 06/09/11

Financial news for VRTX dated on 2011-06-09: Vertex Extends Drop, Loses as Much as 12% in Active Trading

Financial news for VRTX dated on 2011-06-09: Benzinga's Top Pre-Market NASDAQ Losers

Financial news for VRTX dated on 2011-06-09: A Peek Into The Market Before The Trading Starts

Financial news for VRTX dated on 2011-06-09: Vertex Pharmaceuticals Announces Interim Phase 2 Data Showed a Combination of VX-770 and VX-809 Improved Function of the Defective Protein that Causes Cystic Fibrosis in People

Financial news for VRTX dated on 2011-06-09: Vertex Pharmaceuticals Announces Interim Phase 2 Data Showed a Combination of VX-770 and VX-809 Improved Function of the Defective Protein that Causes Cystic Fibrosis in People

Financial news for VRTX dated on 2011-06-03: Hepatitis C Virus (HCV) Updates from Biotech/Pharma Stocks

Financial news for VRTX dated on 2011-05-25: Morgan Stanley Reports Vertex Pharmaceuticals

Financial news for VRTX dated on 2011-05-24: UPDATE: J.P. Morgan Raises PT on Vertex Pharmaceuticals to \$53

Financial news for VRTX dated on 2011-05-24: Bank Of America Comments On Vertex Pharmaceuticals FDA Approvals

Financial news for VRTX dated on 2011-05-24: JP Morgan Raises PT On Vertex Pharmaceuticals To \$53

Financial news for VRTX dated on 2011-05-23: UPDATE: Vertex: Incivek Priced At \$49,200 For 12 Weeks -Dow Jones

Financial news for VRTX dated on 2011-05-23: UPDATE: FDA approves Vertex Incivek for hepatitis C

Financial news for VRTX dated on 2011-05-23: Vertex Hepatitis C Drug Approved by the FDA -Bloomberg

Financial news for VRTX dated on 2011-05-18: GlaxoSmithKline and Isis Pharmaceuticals partnership shouldn't be overlooked as a long-term

Financial news for VRTX dated on 2011-05-17: Biotech/Pharma Stocks News Alert; Hepatitis C Virus (HCV) FDA News from Aethlon Medical, Vertex Pharmaceuticals, Merck & Company

Financial news for VRTX dated on 2011-05-17: Biotech/Pharma Stocks Alert; Hepatitis C Virus (HCV) FDA News from (OTCBB: AEMD), (NYSE: MRK), (VRTX)

Financial news for VRTX dated on 2011-05-17: Biotech/Pharma Stocks Alert; Hepatitis C Virus (HCV) FDA News from (OTCBB: AEMD), (NYSE: MRK), (VRTX)

Financial news for VRTX dated on 2011-05-16: Morgan Stanley Maintains Underweight on Vertex Pharmaceuticals (VRTX)

Financial news for VRTX dated on 2011-05-16: J.P. Morgan Reiterates Neutral on Vertex Pharmaceuticals (VRTX)

Financial news for VRTX dated on 2011-05-16: Piper Jaffray Reiterates Overweight on Vertex Pharmaceuticals (VRTX)

Financial news for VRTX dated on 2011-05-13: Biotech/Pharma Stock News Alert: (OTCBB: AEMD), (NYSE: MRK), (VRTX) Progress on Potential New Treatments for Hepatitis C Virus (HCV)

Financial news for VRTX dated on 2011-05-13: Biotech/Pharma Stocks: (OTCBB: AEMD), (NYSE: MRK), (VRTX) Progress on Potential New Treatments for Hepatitis C Virus (HCV)

Financial news for VRTX dated on 2011-05-13: Biotech/Pharma Stocks: (OTCBB: AEMD), (NYSE: MRK), (VRTX) Progress on Potential New Treatments for Hepatitis C Virus (HCV)

Financial news for VRTX dated on 2011-05-11: Goldman Sachs Suggests Buying Calls on Vertex Pharmaceuticals (VRTX)

Financial news for VRTX dated on 2011-05-10: Market updates- BG Group, Celanese, InterContinental Hotels, Imperial Tobacco, Schroders, CE, IHG, IMT, SDR, BG, VRTX,

SLXP

Financial news for VRTX dated on 2011-05-09: Goldman Sachs Suggests Buying Calls on Vertex Pharmaceuticals (VRTX)

Financial news for VRTX dated on 2011-05-09: Vertex may be an Acquisition Target, Goldman Sachs Says -Bloomberg (VRTX, GS)

Financial news for VRTX dated on 2011-05-04: May Catalysts for Biotech and Drug Stocks

Financial news for VRTX dated on 2011-05-04: VRTX Revenue Above Goldman Sachs Estimate

Financial news for VRTX dated on 2011-05-04: Benzinga's Top Downgrades (VRTX, DGI, KAR, CCC)

Financial news for VRTX dated on 2011-05-02: J.P. Morgan Maintains Neutral on Vertex Pharmaceuticals (VRTX)

Financial news for VRTX dated on 2011-04-28: FDA Advisory Committee Unanimously Recommends Approval of Telaprevir for People with Hepatitis C (VRTX)

Financial news for VRTX dated on 2011-04-28: FDA Panel Recommends Vertex's Telaprevir In 18-0 Vote -Bloomberg (VRTX)

Financial news for VRTX dated on 2011-04-26: Vertex Stock Booms After FDA Reports New Drug is Effective (VRTX)

Financial news for VRTX dated on 2011-04-26: Vertex Jumps Over 13% Higher After FDA Results (VRTX)

Financial news for VRTX dated on 2011-04-26: Update: Vertex Hepatitis C Drug is Effective -Bloomberg (VRTX)

Financial news for VRTX dated on 2011-04-26: Vertex Hepatitis C Drug Is Effective, FDA Reviewers Say -Bloomberg (VRTX)

Financial news for VRTX dated on 2011-04-07: Citi Rates Vertex Pharmaceuticals High-Risk (VRTX)

Financial news for VRTX dated on 2011-04-07: Vertex and Cystic Fibrosis Foundation Therapeutics to Collaborate on Discovery and Development of New Medicines to Treat the Underlying Cause of Cystic Fibrosis

Financial news for VRTX dated on 2011-04-01: April Catalysts For Biotech And Drug Stocks

Financial news for VRTX dated on 2011-04-01: Piper Jaffray Comments On Vertex Pharmaceuticals' Phase III REALIZE Results

Financial news for VRTX dated on 2011-03-31: Vertex Data From Phase 3 Studies Showed Substantial Improvements in SVR Rates With Telaprevir-Based Therapy Compared to Currently Available Medicines in People With Hepatitis C

Financial news for VRTX dated on 2011-03-31: Vertex Pharmaceuticals Announces Results From Phase 3 REALIZE Study Showed Telaprevir-Based Therapy Significantly Improved SVR Rates in People Whose Prior Treatment For Hepatitis C Was Unsuccessful

Financial news for VRTX dated on 2011-03-31: Piper Jaffray Reiterates Overweight on Vertex Pharmaceuticals (VRTX)

Financial news for VRTX dated on 2011-03-31: Piper Jaffray Comments On EASL Meeting With Vertex

Financial news for VRTX dated on 2011-03-31: A Peek Into The Market Before The Trading Starts

Financial news for VRTX dated on 2011-03-31: Vertex Announces Interim Phase 2 Data Showed Rapid Viral Response to VX-222 in Combination with Telaprevir, Pegylated-Interferon and Ribavirin Among People With Hepatitis C

Financial news for VRTX dated on 2011-03-29: Vertex Phase 3 Data: Absolute Improvement +12.5% Vs. Placebo, No Discontinuations (VRTX)

Financial news for VRTX dated on 2011-03-29: Vertex Pharmaceuticals Phase 3 Study of VX-770 in Children Ages 6 to 11 With a Specific Type of Cystic Fibrosis Showed Profound Improvements in Lung Function and Other Measures of Disease

Financial news for VRTX dated on 2011-03-25: Goldman Sachs Comments On Management Meetings With Vertex Pharmaceuticals

Financial news for VRTX dated on 2011-03-24: J.P. Morgan Maintains Neutral on Vertex Pharmaceuticals (VRTX)

Financial news for VRTX dated on 2011-03-07: Vertex Pharmaceuticals Announces That 15 abstracts on Company's Medicines in Development for Hepatitis C Were Accepted for Presentation at EASL Annual Meeting

Financial news for VRTX dated on 2011-03-07: Piper Jaffray Comments On Share Surge For Vertex Pharmaceuticals

Financial news for VRTX dated on 2011-03-03: Benzinga's Top ETF Decliners, March 3rd (EDZ, SQQQ, TYP, VXX)

Financial news for VRTX dated on 2011-03-03: Benzinga's Top ETF Gainers, March 3rd (TNA, TQQQ, EDC, FAS)

Financial news for VRTX dated on 2011-03-03: Citi Reports VX-770 Is Helping Investors Breathe Easier For Vertex Pharmaceuticals

Financial news for VRTX dated on 2011-03-03: Citigroup Raises PT On Vertex Pharmaceuticals To \$51

Financial news for VRTX dated on 2011-03-02: Vertex Pharmaceuticals Presents Positive Phase 2 Interim Data from First Study of Telaprevir

Financial news for VRTX dated on 2011-02-24: Wedbush Upgrades Vertex Pharmaceuticals to Outperform

Financial news for VRTX dated on 2011-02-24: Goldman Sachs Suggest Buying Calls on Vertex Pharmaceuticals (VRTX)

Financial news for VRTX dated on 2011-02-24: Top 4 Mid-Cap Stocks In The Drug Manufacturers-Other Industry With The Highest Cash (WCRX, VRTX, ENDP, UTHR)

Financial news for VRTX dated on 2011-02-23: Vertex Pharmaceuticals Announce Results From STRIVE And Discover Trials

Financial news for VRTX dated on 2011-02-23: Options Brief: Vertex Pharmaceuticals (VRTX)

Financial news for VRTX dated on 2011-02-23: Benzinga's Volume Movers (VRTX, NDSN, OCLR, GRMN)

Financial news for VRTX dated on 2011-02-23: J.P. Morgan Maintains Neutral on Vertex Pharmaceuticals (VRTX)

Financial news for VRTX dated on 2011-02-23: Benzinga's Top Pre-Market NASDAQ Gainers (VRTX, OCLR, JASO, AMAT)

Financial news for VRTX dated on 2011-02-22: J.P. Morgan Reiterates Vertex Neutral, Maintains \$43 PT (VRTX)

Financial news for VRTX dated on 2011-02-09: Goldman Sachs Suggests Buying Calls on Vertex Pharmaceuticals (VRTX)

Financial news for VRTX dated on 2011-02-08: Goldman Sachs Initiates Neutral Rating on Smid-Cap Biotech (UTHR, VRTX, AMLN)

Financial news for VRTX dated on 2011-02-08: Goldman Says Buy Vertex Pharmaceuticals Options (VRTX)

Financial news for VRTX dated on 2011-02-07: Options Brief: Vertex Pharmaceuticals (VRTX)

Financial news for VRTX dated on 2011-02-04: Piper Jaffray Reiterates Vertex Pharmaceuticals Overweight, \$48 PT (VRTX)

Financial news for VRTX dated on 2011-02-04: J.P. Morgan Rasies Vertex Pharmaceuticals PT To \$43 (VRTX)

Financial news for VRTX dated on 2011-01-25: J&J Disappoints, 2011 Outlook Weak - Analyst Blog

Financial news for VRTX dated on 2011-01-25: J&J Disappoints, 2011 Outlook Weak - Analyst Blog

Financial news for VRTX dated on 2011-01-21: Priority Review for Vertex HCV Drug - Analyst Blog

Financial news for VRTX dated on 2011-01-21: Priority Review for Vertex HCV Drug - Analyst Blog

Financial news for VRTX dated on 2011-01-10: Vertex Expects an Eventful 2011 - Analyst Blog

Financial news for VRTX dated on 2011-01-10: Vertex Expects an Eventful 2011 - Analyst Blog

Financial news for VRTX dated on 2011-01-10: J.P. Morgan Maintains Neutral Rating On VRTX

Financial news for VRTX dated on 2011-01-10: J.P. Morgan Healthcare Confab: Live Blog

Financial news for VRTX dated on 2011-01-07: Priority Review for Merck's HCV Drug - Analyst Blog

Financial news for VRTX dated on 2011-01-07: Priority Review for Merck's HCV Drug - Analyst Blog

Financial news for VRTX dated on 2011-01-06: Piper Jaffray Overweight On Vertex Pharmaceuticals (VRTX)

Financial news for VRTX dated on 2011-01-05: Biotech 2011 Kickoff Party: Investor Preview

Financial news for VRTX dated on 2010-12-20: Monday's Put/Call Ratio Leaders (PKX, GMXR, GRA, VRTX, SLB)

Financial news for VRTX dated on 2010-12-20: Options Brief: Vertex Pharmaceuticals (VRTX)

Financial news for VRTX dated on 2010-12-10: Wells Fargo Resumes Coverage On VRTX With A \$44-\$48 Valuation Range

Financial news for VRTX dated on 2010-12-03: Biotech Stock Mailbag: Amarin

Financial news for VRTX dated on 2010-12-01: Piper Jaffray On Vertex Pharmaceuticals

Financial news for VRTX dated on 2010-11-24: Vertex Eyes Telaprevir Approval - Analyst Blog

Financial news for VRTX dated on 2010-11-24: Vertex Eyes Telaprevir Approval - Analyst Blog

Financial news for VRTX dated on 2010-11-23: Vertex Files for Hep C Drug Approval

Financial news for VRTX dated on 2010-10-28: Loss Widens for Vertex - Analyst Blog

Financial news for VRTX dated on 2010-10-27: Some Lesser Known Popular ETFs (IVV, MDY, IJR)

Financial news for VRTX dated on 2010-10-26: From A Financial Perspective, Vertex Pharmaceuticals Q3 Is Uneventful

Financial news for VRTX dated on 2010-10-26: VRTX EPS In-Line With Estimates; Could Launch Blockbuster Drug in 2011

Financial news for VRTX dated on 2010-10-25: Vertex Pharmaceuticals Posts Mixed Results (VRTX)

Financial news for VRTX dated on 2010-10-25: Vertex Pharmaceuticals Reports Third Quarter Results; EPS (\$.87)

Financial news for VRTX dated on 2010-10-13: Vertex To Present Data On Recent Pharma Studies

Financial news for VRTX dated on 2010-10-07: Coverage Initiated On: (EFX, GME, BBT, ECOL, VRTX)

Financial news for VRTX dated on 2010-09-24: Vertex Pharmaceuticals Announces Exercise of Underwriter's Option to Purchase Senior Notes (VRTX)

Financial news for VRTX dated on 2010-09-23: Benzinga's Top Pre-Market NASDAQ Losers (CVVT, NOVL, TIVO, VRTX)

Financial news for VRTX dated on 2010-09-22: Vertex Pharmaceuticals Announces Proposed \$375M Public Offering

Financial news for VRTX dated on 2010-09-13: Oppenheimer's Current Biotech Ratings

Financial news for VRTX dated on 2010-09-08: Vertex's Telaprevir Encourages - Analyst Blog

Financial news for VRTX dated on 2010-09-08: Vertex Reports Solid REALIZE Data

Financial news for VRTX dated on 2010-09-08: Oppenheimer Sees 30% Upside In Vertex Pharmaceuticals (VRTX)

Financial news for VRTX dated on 2010-08-18: 2H:10 Milestones In Drug Discovery (ARNA, VRTX, REGN, EXEL)

Financial news for VRTX dated on 2010-08-17: Oppenheimer Remains Buyer Of VRTX

Financial news for VRTX dated on 2010-07-28: Vertex Pharmaceuticals; Earnings Mixed (VRTX)

Financial news for VRTX dated on 2010-07-01: Upside Purchased on Vertex Pharma (VRTX)

Financial news for VRTX dated on 2010-06-30: Calls Purchased on Vertex Pharmaceuticals (VRTX)

Financial news for VRTX dated on 2010-06-23: Piper Jaffray Retains Overweight Rating For Vertex Pharma (VRTX)

Financial news for VRTX dated on 2010-06-21: Mad Money Lightning Round: Cramer Prefers CRUS Over CREE

Financial news for VRTX dated on 2010-06-19: Mad Money Lightning Round: Cramer Gives His Opinion On VRTX, GMCR, SJM, CREE, STD, S, FAF, SPW

Financial news for VRTX dated on 2010-06-01: Vertex Pharmaceuticals To Present at Two Investor Conferences (VRTX)

Financial news for VRTX dated on 2010-05-26: Focus Shifts Back to Domestic Issues 05-26-2010

Financial news for VRTX dated on 2010-05-26: Benzinga's Volume Movers (VRTX, CETV, NAFC, RMBS)

Financial news for VRTX dated on 2010-05-26: Positive ADVANCE Phase III Data Should Act As A Catalyst For JNJ

Financial news for VRTX dated on 2010-05-26: Benzinga's Top Pre-Market Gainers (CJBK, TSCM, SOLF, LTXC, VRTX)

Financial news for VRTX dated on 2010-05-25: Benzinga's After Hours Gainers (VRTX, EXC, VVUS)

Financial news for VRTX dated on 2010-05-14: VRTX Initiated With Market Perform At Wells Fargo

Financial news for VRTX dated on 2010-04-09: VRTX Well Positioned To Capture Initial Paradigm Shift In Hep C Therapy

Financial news for VRTX dated on 2010-04-09: BIB, BIS: New Biotech 2x ProShares

Financial news for VRTX dated on 2010-04-08: ThinkEquity Rates Vertex Pharmaceuticals (VRTX) A Hold

Financial news for VRTX dated on 2010-03-30: Vertex Pharmaceuticals Incorporated (VRTX) Maintains Overweight Rating

Financial news for VRTX dated on 2010-03-21: How Will Obama-Care Play Into The Markets And ETFs?

Financial news for VRTX dated on 2010-03-15: Investors Are Turning To Small and Mid Cap ETFs In 2010

Financial news for VRTX dated on 2010-03-09: Top Takeover Targets In The Biotechnology Sector This Year (VRTX, AUXL, CELG, ITMN, GENZ)

Financial news for VRTX dated on 2010-03-03: Jim Cramer Comments On PMCS, CSCO, VRTX, GILD, PAL

Financial news for VRTX dated on 2010-03-03: Mike Huckman Is Watching VRTX, DNDN, HGSI

Financial news for VRTX dated on 2010-02-05: Vertex Pharmaceuticals, Inc. (VRTX) Maintains Buy Rating

Financial news for VRTX dated on 2010-02-01: Vertex Pharmaceuticals Inc. (VRTX) Upgraded To Outperform

Financial news for VRTX dated on 2010-02-01: Strong Product Pipeline At VRTX

Financial news for VRTX dated on 2010-01-13: Vertex Pharma (VRTX) To File For Hepatitis Drug Approval

Financial news for VRTX dated on 2010-01-11: Vertex Expects a Net Loss of Less Than \$650 Million for 2009 (VRT)

Financial news for VRTX dated on 2010-01-05: Benzinga's Top Downgrades (VRTX, V, CXO, BEXP, COG)

Financial news for VRTX dated on 2009-12-03: Index Futures Surge As Bank Of America (BAC) Is Set To Repay \$45 Billion Government Bail Out Fund

Financial news for VRTX dated on 2009-11-23: Shafran Talks About His Tech Stock Picks With Barron's: PNR, ADS, TLVT, VRTX, CREE, AZPN

Financial news for VRTX dated on 2009-11-02: Stocks Running Early (HGSI, VRTX, DNDN, JWN)

Financial news for VRTX dated on 2009-09-30: Fast Money Crew Like FTO, VRTX, BAC, DIS

Financial news for VRTX dated on 2009-08-10: TheFortuneFinancial.com Free Market Research on BVF, TTI, WTI, DRC, VRTX and SBIB